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                                                 The most beautiful thing we can experience is the mysterious. 
                                                                                It is the source of all true art and science. 
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ABSTRACT 
Most cases of cancer, when detected at an advanced stage, cannot be cured with conventional 
therapeutic modalities. Therefore, novel approaches such as gene therapy are needed. Nevertheless, 
while the safety record of gene therapy for cancer has been excellent, clinical efficacy has so far 
been limited. Moreover, it has become evident that clinical efficacy is directly determined by gene 
delivery efficacy. Most adenoviruses used for gene therapy have been based on serotype 5 (Ad5). 
Unfortunately, expression of the primary receptor for Ad5 (coxsackie-adenovirus receptor, CAR) is 
highly variable on ovarian and other cancer cells, resulting in resistance to infection. Consequently, 
various strategies have been evaluated to modify adenovirus tropism in order to circumvent CAR 
deficiency, including retargeting complexes or genetic capsid modifications.  
By performing genetic fiber pseudotyping, we created Ad5/3 chimeric vectors possessing the 
receptor binding fiber knob protein from serotype 3 in the otherwise Ad5 derived capsid. This 
genetically modified virus is therefore retargeted to the distinct but currently unknown Ad3 
receptor. We found high expression of the Ad3 receptor on ovarian cancer cells, and importantly, 
this correlated with the enhanced infectivity of the target cells as compared to a virus with the 
serotype 5 capsid.  
Further, the murine liver toxicity, blood clearance and biodistribution profiles were comparable to 
Ad5. These might be favorable features, as Ad5 based viruses have displayed excellent safety 
profile in clinical cancer gene therapy trials. Importantly, Ad5/3 chimerism could be useful as a 
means for circumventing preexisting neutralizing anti-adenovirus antibodies present in serum and 
ascites fluid.   
To further improve tumor penetration and local amplification on the anti-tumor effect, selectively 
oncolytic agents, i.e. conditionally replicating adenoviruses (CRAds), have been constructed. 
Infection of tumor cells results in replication, oncolysis, and subsequent release of the virus 
progeny. Normal tissue is spared due to lack of replication. Further, these viruses are potentially 
attractive therapeutics for cancer because they selectively amplify the input treatment dose in target 
cells. However, the oncolytic potency of replicating agents is directly determined by their capability 
of infecting target cells.  
Thus, we created Ad5/3-∆24, the first selectively oncolytic adenovirus which does not bind CAR. 
This virus has a 24-bp deletion in the E1A gene, and therefore, the expressed E1A protein is unable 
to bind retinoblastoma (Rb) protein, which normally allows S-phase entry, needed for virus 
replication. Thus, this virus preferentially replicates in and lyses cells with an inactive Rb/p16 
pathway. Ad5/3 chimerism resulted in dramatically enhanced infectivity of ovarian cancer cells, 
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which translated into increased oncolysis of target cells. Replication was also analyzed with 
quantitative PCR on three-dimensional primary tumor cell spheroids purified fresh from patient 
samples. Further, the anti-tumor efficacy in orthotopic animal models of ovarian cancer was 
impressive. Finally, Ad5/3-∆24 achieved a significant anti-tumor effect as assessed by non-
invasive, in vivo bioluminescence imaging.  
Next, we hypothesized that a CRAd expressing an inert soluble protein, which could be monitored 
in growth medium or serum, might give information about the persistence or antitumor efficacy of 
CRAds. Consequently, we constructed Ad5/3-∆24-hCEA, which features a secreted marker protein, 
soluble human carcinoembryogenic antigen (hCEA). We found that virus replication closely 
correlated with hCEA secretion. Further, antitumor efficacy and persistence of the virus could be 
deduced from plasma hCEA levels. Finally, using in vivo bioluminescence imaging, we were able 
to detect effective tumor cell killing by the virus, which led to enhanced therapeutic efficacy and 
increased survival of mice with disseminated ovarian cancer. 
The preclinical therapeutic efficacy of Ad5/3-∆24 is improved over the respective CAR-binding 
controls. Taken together with promising biodistribution and toxicity data, this approach could 
translate into successful clinical interventions for ovarian cancer patients. 
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REVIEW OF THE LITERATURE 
1. Introduction 
Adenovirus-mediated gene therapy has been proposed as a treatment alternative for advanced 
cancers refractory to traditional therapies (Russell. 2000). Adenoviruses are attractive vectors for 
cancer due to their unparalleled capacity for gene transfer and stability in vivo. Also, the production 
of high titers of current good manufacturing practices (cGMP) quality adenoviruses is well 
established. From a safety standpoint, it is important that the wild-type virus usually causes only 
mild, well characterized human disease. Additionally, adenoviruses have been well studied since 
their description in the 1950s, and in contrast to many other types of viruses proposed for utilization 
in gene therapy, we have a reasonable understanding of adenovirus biology (Russell. 2000). 
Further, adenovirus DNA is not integrated into the host genome, and the risk of insertional 
mutagenesis is low. Adenovirus cannot infect oocytes, and therefore, no female germ-line 
transduction has been noted (Gordon. 2001). 
The human adenovirus is a non-enveloped icosahedral particle that encapsulates a 36 kb double-
stranded DNA genome (Figure 1a). Hexon is the most abundant structural protein. Penton base 
units are located at each of the twelve vertices of the capsid, and the twelve fiber homo-trimers 
protrude from the penton bases. Hexon appears to play a structural role as a coating protein, while 
the penton base and fiber are responsible for cellular attachment and internalization. As shown in 
Figure 1b, initial high-affinity binding of the most common adenoviral gene therapy vector, 
serotype 5 (Ad5), occurs via direct binding of the fiber knob domain to the primary receptor, the 
coxsackie-adenovirus receptor (CAR) (Bergelson et al. 1997; Tomko et al. 1997). Cell surface 
binding is followed by internalization of the virus, mediated by the interaction of a penton base 
arginine-glycine-aspartic acid (RGD) motif and cellular αvβ integrins (Wickham et al. 1993), which 
triggers endocytosis of the virion via clathrin-coated pits (Wang et al. 1998). In the endosome, the 
virus is disassembled followed by endosomal lysis. Thereafter, viral DNA is transported to the 
nucleus through a microtubule-mediated process, and viral genes are expressed (Leopold et al. 
2000). The adenoviral genome can be divided into immediately early (E1A), early (E1B, E2, E3, 
E4), intermediate (IX, IVa2) and late genes (Figure 2). The latter encode structural proteins, while 
the early genes encode mainly regulatory proteins that prepare the host cell for virus DNA 
replication and block antiviral mechanisms. The E1A protein and its binding to the retinoblastoma 
(Rb) protein leads to the release of E2F family transcription factors, which force the host cell into 
S-phase. Further, to prevent apoptosis the adenovirus utilizes E1B proteins. Proteins encoded from 
the E3 region regulate host immune responses and enhances cell lysis and release of virus progeny. 
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Recently, it has been suggested that the binding of adenovirus to its primary receptor may be an 
important rate-limiting step for gene transfer, i.e. lack of CAR could make target tissues refractory 
(Bauerschmitz et al. 2002a; Hemminki and Alvarez. 2002a; Miller et al. 1998; Zabner et al. 1997; 
Seidman et al. 2001; Okegawa et al. 2001; Cohen et al. 2001; Shayakhmetov et al. 2002; Li et al. 
1999; Cripe et al. 2001; Nalbantoglu et al. 1999; You et al. 2001). Indeed, recent data suggests that 
although CAR is expressed ubiquitously on most normal epithelial cells, CAR expression in tumors 
may be highly variable resulting in resistance to Ad5 infection (Bauerschmitz et al. 2002a; Miller et 
al. 1998; Shayakhmetov et al. 2002; Li et al. 1999; Cripe et al. 2001; Dmitriev et al. 1998; Kasono 
et al. 1999; Hemmi et al. 1998; Rauen et al. 2002). Specifically, resistance may be due to low 
expression levels, or aberrant localization at the cellular or tissue level (Anders et al. 2003a). 
Further, there may be inverse correlation with tumor grade, and also between activity of the 
RAS/MAPK pathway and CAR expression (Anders et al. 2003b). The function of CAR is not fully 
understood, but its localization in the tight junctions suggests a role in cell adhesion (Cohen et al. 
2001). Interestingly, it might have tumor suppressing activity (Okegawa et al. 2001).  
 
 
Figure 1. a) Adenovirus virion. Major structural components of a wild-type Ad5 are shown. Adenovirus capsid contains up 
to 36 kb double-stranded DNA genome. b) Adenovirus infection pathway. Cell entry is initiated by high-affinity binding of 
the fiber knob domain to its primary receptor, CAR. CAR-binding is followed by endocytosis mediated by penton base RGD 
interaction with cellular αvβ integrins. After endosomal lysis, viral DNA is transported to the nucleus through a microtubule-
mediated process, and viral genes or transgenes are expressed. 
 
Despite exciting preclinical data, adenoviral cancer gene therapy approaches utilizing various 
strategies have yet to display definitive clinical breakthroughs. In general, this result has been 
attributed to insufficient transduction of tumor cells. Understanding of the adenoviral cellular entry 
pathway gave rise to the strategy of transductional targeting. Consequently, various approaches 
  
                                                                  12   
have been evaluated to modify adenovirus tropism in order to circumvent CAR deficiency, 
including retargeting complexes or genetic capsid modifications. Further, certain chemical agents 
have shown to increase CAR expression in vitro and in vivo. Specifically, these reagents affect cell 
cycle or cell adhesion (Hemminki et al. 2003a). 
 
 
Figure 2. Generalized map of adenovirus genome. Adenovirus transcription can be defined largely as a two-phase event, 
early and late. The early genes (E1-E4) regulate adenovirus transcription, induct cell growth, prevent apoptosis, modulate the 
host immune response to adenovirus infection and promote virion release. Late phase gene expression is driven primarily by 
the major late promoter. A complex series of splicing events results in five gene clusters (L1-L5) encoding mostly virion 
proteins. LITR = left inverted terminal repeat, Ψ = packaging signal, MLP = major late promoter, RITR = right inverted 
terminal repeat. 
 
However, adenovirus biodistribution is not determined by CAR expression alone. In fact, 
intravascular adenovirus delivery results in accumulation mainly in the liver, spleen, heart, lung and 
kidneys of mice, although these tissues may not necessarily be the highest in CAR expression 
(Fechner et al. 1999). Instead, the degree of blood flow, and the structure of the vasculature in each 
organ probably contribute to the biodistribution. Importantly, tissue macrophages, such as Kupffer 
cells of the liver, have a major role in clearing adenovirus from blood (Worgall et al. 1997; 
Alemany et al. 2000). This is a non-CAR mediated process, and results in rapid blood-clearance and 
virus degradation. However, Kupffer cells can be saturated with ca. 1-2 x 1010 viral particles (vp) in 
mice, and thereafter virus delivery to other organs is increased (Tao et al. 2001). Alternatively, 
Kupffer cells can be depleted. It is currently unknown, if these aspects are similar in humans 
(Worgall et al. 1997; Alemany et al. 2000; Wolff et al. 1997).  
Finally, adenovirus may be able to utilize other cellular receptors besides CAR and αvβ integrins for 
cell entry. Recent studies have suggested that major histocompatibility complex I (MHC I) (Hong et 
al. 1997) and heparan sulfate glycosaminoglycans (HSG) (Dechecchi et al. 2001; Smith et al. 2003) 
may be involved in virus binding. Importantly, HSG-binding by the fiber shaft Lysine-Lysine-
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Threonine-Lysine (KKTK) motif might influence in vivo hepatocyte transduction (Smith et al. 
2003). 
 
2. Transductionally targeted adenoviruses 
Transductional targeting of adenovirus aims at enhanced or specific transduction of the target cell. 
The goal is to delete the broad tropism of Ad5 towards normal epithelial cells, and/or enhance virus 
infectivity of CAR-deficient tumor cells. Strategies to redirect adenovirus binding to other cellular 
receptors than CAR include bispecific molecules that block the interaction with CAR and redirects 
the virus to a novel receptor (Figure 3b), and genetic retargeting, in which the virus particle is 
genetically modified (Figure 3c).  
 
 
 
Figure 3. Transductional retargeting. a) Ad5 binds to CAR in the normal cells. b) Adapter molecule can retarget the 
adenovirus binding to the alternative receptor. sCAR-EGF fusion protein targets the binding to EGFR overexpressed in 
many cancers (Hemminki et al. 2001a). c) Receptor binding knob domain can be genetically modified to achieve CAR-
independent binding to a tumor associated receptor. 
 
2.1. Conjugate-based retargeting 
In the two-component conjugate-based strategy, adapters typically have been designed to have 
specific recognition for the knob domain of the adenovirus fiber. Various chemical conjugates 
between the Fab fragment of an anti-knob monoclonal antibody and natural ligands specific for cell 
surface receptors [folate (Douglas et al. 1996) or basic fibroblast growth factor (FGF2) (Goldman et 
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al. 1997; Rancourt et al. 1998; Gu et al. 1999; Printz et al. 2000)] have been used successfully. 
Also, anti-receptor antibodies [anti-epidermal growth factor receptor (anti-EGFR) (Miller et al. 
1998), anti-epithelial cellular adhesion molecule (anti-EpCAM) (Haisma et al. 1999), anti-tumor 
associated glycoprotein 72 (TAG-72) (Kelly et al. 2000), anti-CD40 (Tillman et al. 2000)] have 
been conjugated to anti-knob Fab. 
The initial in vitro proof of principle study was performed by Douglas et al., with a Fab-folate 
conjugate. This retargeting resulted in CAR-independent, folate receptor-mediated transduction of 
cancer cells highly expressing the folate receptor (Douglas et al. 1996). A Fab-FGF2 adapter was 
utilized to target adenoviruses to FGF receptor-positive ovarian cancer cells in vitro. It was also 
used to retarget herpes simplex virus type I thymidine kinase (HSV-TK) expressing adenovirus to 
ovarian cancer cells, resulting in enhanced survival of ovarian cancer xenograft-bearing mice 
(Rancourt et al. 1998). These findings led to a clinical trial protocol for intraperitoneal (i.p.) 
treatment of ovarian cancer patients with peritoneally disseminated disease with a Fab-FGF2 
targeted adenovirus coding for HSV-TK (A Hemminki, personal communication). Importantly, the 
antibody mediated targeting method has been evaluated in vivo with systemic administration, 
utilizing a bispecific antibody between the adenovirus fiber and angiotensin-converting enzyme 
(Reynolds et al. 2000). This vector showed a more than 20-fold increase in transgene expression 
and virus DNA localization in the lungs. Finally, bispecific antibodies have been designed to bind 
to FLAG-modified penton base (Wickham et al. 1996) or hexon protein (Yoon et al. 2000) instead 
of knob.  
Recent studies have utilized a truncated, soluble form of CAR (sCAR) as a knob-binding 
component in a recombinant fusion molecule consisting of sCAR fused to epidermal growth factor 
(EGF) (Dmitriev et al. 2000) (Figure 3b). Up to a 9-fold increase in reporter gene expression was 
achieved in several EGFR-overexpressing cancer cell lines compared to untargeted adenovirus in 
vitro (Dmitriev et al. 2000). To further increase adenovirus-sCAR-ligand complex stability, a 
trimeric sCAR-fibritin-anti-erbB2 single chain antibody targeting molecule was created, and it 
increased gene transfer in c-erbB2-positive breast and ovarian cancer cell lines in vitro 
(Kashentseva et al. 2002).   
2.2. Genetic targeting strategies   
Two-component retargeting strategies add complexity to the system, which might be 
disadvantageous in clinical trials. Further, there might be variations in the amount of retargeting 
conjugates bound to each virion, and the stability of adenovirus-conjugate-complexes in humans is 
not known. Therefore, genetic modifications of the adenovirus capsid for incorporation of targeting 
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moieties have been created (Figure 3c). This results in homogenous population of retargeted 
vectors.  
Wickham et al. modified the knob domain of the fiber protein by adding peptides to the C-terminus 
of the protein (Wickham et al. 1997) (Figure 4b). Adenoviruses with C-terminal αvβ integrin-
binding RGD motifs and heparan sulfate-binding polylysine residues have yielded some promising 
results in vitro and in vivo, but other, larger peptides result in inefficient packaging of the virion, 
possibly due to inability of the modified fiber to trimerize (Wickham et al. 1997; Hong and Engler. 
1996). After the crystal structure of the Ad5 fiber was revealed (Xia et al. 1994) (Figure 5), another 
knob location was found to possibly possess favorable features for genetic modification. There is an 
exposed HI loop (i.e. between β-strands H and I) in the knob monomer, which can tolerate peptide 
insertions up to 100 amino acids, often with minimal negative effects on virion integrity (Belousova 
et al. 2002) (Figure 4c). First, Krasnykh et al. incorporated a FLAG octapeptide to validate the 
strategy (Krasnykh et al. 1998). Subsequently, other retargeting motifs in the HI loop have been 
evaluated. An RGD-4C peptide (Dmitriev et al. 1998) enhanced the infectivity of wide range of 
tumor cells in vitro and in vivo (Dmitriev et al. 1998; Vanderkwaak et al. 1999; Kasono et al. 1999; 
Wesseling et al. 2001a; Hemminki et al. 2001b; Hemminki et al. 2002b; Grill et al. 2001; Cripe et 
al. 2001), as αvβ integrins are often highly expressed in tumor cells and tumor vasculature. Other 
targeting peptides incorporated into HI loop include Asparagine-Glycine-Arginine (NGR) 
(Mizuguchi et al. 2001) and Serine-Isoleucine-Glycine-Tyrosine-Leucine-Proline-Leucine-Proline 
(SIGYLPLP) (Nicklin et al. 2001). Of note, the combination of C-terminal (polylysine) and HI loop 
(RGD-4C) targeting has also been evaluated (Wu et al. 2002a) (Figure 4d). This double-
modification achieved enhanced transduction over single-modifications. 
However, mere incorporation of heterologous targeting ligands into the knob domain might result in 
vectors with enhanced cell transduction, as opposed to actual retargeting, since the knob domain is 
still able to bind CAR. Nevertheless, if ligand incorporation is combined with ablation of CAR-
binding, as is a case with an endothelial cell binding SIGYLPLP (Nicklin et al. 2001), CAR-
independent retargeting is achieved. Recently, the CAR-binding amino acid residues of the knob 
were identified. The binding site consists of a non-linear amino acid sequence in the AB loop, B β-
sheet and DE loop, and the mutation of these residues can ablate CAR-binding (Roelvink et al. 
1999). 
The complete knob can be deleted, and replaced with a retargeting ligand (Figure 4e). However, the 
chimeric fiber protein must be able to assemble into a trimer, as the knob domain normally initiates 
trimerization (Hong and Engler. 1996), which is required for proper fiber function. Further, these 
chimeric fibers must be able to localize to the nucleus for capsid assembly. Magnusson et al. solved 
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the problem with an external trimerization signal, a neck region peptide (NRP) of human surfactant 
protein D, which had the RGD ligand attached with a linker (Magnusson et al. 2001). This 
modification resulted in selective infection of integrin-expressing cell lines in vitro. Another 
strategy for deknobbing used the phage T4 fibritin as a fiber protein (Krasnykh et al. 2001). The 
Ad5 tail and immediately proximal part of the shaft were fused with the C-terminal T4 fibritin, 
which is able to trimerize.  A six histidine (6-His) targeting motif was fused via a short peptide 
linker. This retargeted adenovirus lacks the ability to interact with CAR and showed up to a 100-
fold increase in reporter gene expression in cells presenting an artificial 6-His binding receptor. 
 
 
 
Figure 4. Genetic capsid targeting modifications. a) Adenovirus capsid proteins. b) C-terminal ligand in the fiber knob. c) 
Modification of the HI loop. d) The combination of C-terminus and HI loop targeting. e) “Deknobbing”. f) Pseudotyping, 
knob chimerism. g) Pseudotyping, fiber chimerism. h) Targeting ligands in other capsid proteins (pIX, hexon or penton 
base). 
Adenovirus fiber pseudotyping, i.e. alteration of the virus tropism by substituting the receptor-
binding proteins (knob/fiber) with those from other serotypes, has been evaluated (Figure 4f, g). Of 
special interest have been Ad5 based vectors with the knob or fiber from subgroup B adenoviruses, 
which bind other cellular receptors than CAR (Gall et al. 1996; Shayakhmetov et al. 2000; 
Shayakhmetov et al. 2002; Havenga et al. 2002; Mizuguchi and Hayakawa. 2002; Krasnykh et al. 
1996). Resultant vectors have displayed CAR-independent transduction and enhanced infectivity of 
low-CAR target cells. Initially, Karsnykh et al. created an Ad5 vector that expressed a chimeric 
fiber displaying the adenovirus serotype 3 knob domain (Ad5/3) (Krasnykh et al. 1996). Ad5/3 
effectively transduced low-CAR cancer cell lines in vitro, whereas these cells were refractory to 
Ad5 infection. This knob chimerism retargeted the virus to the distinct but currently unknown Ad3 
receptor (Stevenson et al. 1995). Also, other serotype chimeras have been evaluated. Specifically, 
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Ad5/35 chimeras displayed enhanced infectivity of cancer cells and favorable biodistribution 
profile (Mizuguchi and Hayakawa. 2002; Bernt et al. 2003; Shayakhmetov et al. 2002; Knaan-
Shanzer et al. 2001; Havenga et al. 2002). Recent preliminary data suggests that CD46 could be the 
Ad35 receptor, and it might serve as a common receptor for many subgroup B adenoviruses 
(Gaggar et al. 2003). The CD46 membrane cofactor protein is expressed on the surface of all 
nucleated human cells examined to date (Liszewski et al. 1991). CD46 is a ubiquitous type-1 
glycoprotein that is a member of a family of regulators of complement activation, and therefore 
prevents spontaneous activation of complement on autologous cells. Interestingly, CD46 has been 
identified as a primate-specific cellular receptor for human herpesvirus 6 (HHV-6) (Santoro et al. 
1999) and vaccine strains of measles virus (Dorig et al. 1993). 
 
                                                                            
 
 
 
Figure 5. Structure of the adenovirus fiber knob 
domain. The knob trimer resembles a three-bladed 
propeller formed by two sheets of β-strands connected 
with loops and turns. The exposed HI loop is circled 
(picture adapted from Xia et al. 1994). 
 
Attempts to target adenoviruses have also involved genetic modifications of other capsid proteins 
such as penton base, hexon or pIX. Penton base wild-type RGD has been replaced with retargeting 
peptide (Wickham et al. 1995). Hexon hypervariable region 5 (HVR5) is a loop structure localized 
on the surface of the virion, and it was successfully used for incorporation of an RGD motif (Vigne 
et al. 1999). pIX is a minor capsid component whose function may involve stabilization. The C-
terminus of pIX is exposed on the outer surface of the virus capsid.  Dmitriev et al. incorporated a 
polylysine motif at the pIX C-terminus, resulting in augmented, CAR-independent gene transfer via 
binding to cellular heparan sulfate moieties (Dmitriev et al. 2002) (Figure 4h). Finally, serotype 
switching has been used to create hexon chimeras, which circumvented murine pre-existing 
neutralizing Ad5 antibodies (Wu et al. 2002b). 
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3. Transcriptionally targeted adenoviruses 
Transductional targeting approaches attempt to increase vector entry into target cells while reducing 
gene transfer to non-target cells. In contrast, transcriptional targeting does not change the tropism of 
viruses but restricts gene expression to target cells. Transcriptional targeting can be achieved by 
placing a viral gene or transgene under control of a tissue- or tumor-specific promoter (TSP). Such 
viruses are able to infect various cell types, but the viral gene or transgene are expressed only in the 
cell types, which actively express the transcription factors needed for activity of the TSP. 
Numerous TSPs have been evaluated with promising preclinical results (Bauerschmitz et al. 2002a). 
For example, the secretory leukoprotease inhibitor (SLPI) gene is expressed in several different 
carcinomas. Its expression in normal organs, such as the liver, is low (Abe et al. 1997). Therefore, 
the SLPI promoter was utilized to drive transgene expression in ovarian cancer cell lines and 
primary tumor cells. The promoter retained its fidelity in an adenovirus context. Further, a murine 
orthotopic model of peritoneally disseminated ovarian cancer was used to demonstrate high tumor 
gene expression versus low liver expression with the SLPI promoter, and that adenovirus-delivered 
HSV-TK under the control of the SLPI promoter was able to increase survival (Barker et al. 2003a). 
The cyclooxygenase-2 (cox-2) promoter has been explored in the context of gastric cancer, 
pancreatic carcinoma and ovarian cancer (Barker et al. 2003a; Yamamoto et al. 2001; Wesseling et 
al. 2001b; Casado et al. 2001). The cox-2 promoter was active in a panel of epithelial cancer cell 
lines and primary cells. Furthermore, its activity was low in liver and normal mesothelial cells, 
which may be important from a safety standpoint. 
Gene expression from certain promoters can be regulated with radiation. For example, the early 
growth response gene 1 (egr-1) enhancer/promoter, which is radiation inducible, has been used as a 
TSP for specific expression of HSV-TK in glioma cells (Manome et al. 1998). Another regulation 
strategy is the use of hypoxia-inducible promoters (Binley et al. 2003), and finally, a combination 
of these two modalities (Greco et al. 2002). Further, regulation can be achieved with chemically 
inducible promoters. For example, a tetracycline-activated promoter can be used to regulate gene 
expression and subsequent protein production by oral tetracycline (Fechner et al. 2003). Withdrawal 
of the drug rapidly abrogates gene expression. 
 
4. Double-targeted adenoviruses 
TSPs can reduce the side effects of cancer gene therapy approaches, as transgene/viral gene 
expression is restricted to cells capable of activating the TSP, which thereby mitigates toxicity to 
normal cells. As the liver is the organ responsible for uptake and degradation of the majority of 
  
                                                                  19   
adenovirus, regardless of the route of administration, it is also the most relevant organ with regard 
to evaluation of a candidate TSP. This is compounded by the Pennsylvania gene therapy fatality, 
which was probably caused by a Kupffer cells launching an aberrant hyperimmune reaction to a 
very large dose of adenovirus delivered via the hepatic artery into a liver already damaged by the 
underlying disease (Raper et al. 2003). Nevertheless, it is remarkable that more than 1000 cancer 
patients have been treated with adenovirus, without mortality attributable to the treatment 
(Hemminki and Alvarez. 2002a). Transductional and transcriptional targeting can be combined to 
create double-targeted viruses. Conceivably, this approach could be synergistic with regard to 
safety and efficacy. Double targeting for ovarian cancer has been achieved in vitro and in vivo. 
Transductional targeting with a sCAR-fibritin-anti-erbB2 adapter was able to increase gene transfer 
to target cells while reducing transduction of non-target cells (Kashentseva et al. 2002). When 
combined with transcriptional targeting with the SLPI promoter, an increase in selectivity was seen 
(Barker et al. 2003b). Reynolds et al. combined the conjugate-based pulmonary vascular targeting, 
i.e. the bispecific antibody between the adenovirus fiber and angiotensin-converting enzyme, with 
the use of an endothelial cell-specific promoter flt-1. The dual-targeting resulted in a synergistic 
improvement in the specificity of transgene expression in the pulmonary target cells (over 300 000-
fold improvement compared with untargeted vector) (Reynolds et al. 2001). 
 
5. Conditionally replicating adenoviruses (CRAds) 
Although chemotherapeutics and radiation therapy target various different cellular structures and 
pathways, most of them kill cancer cells by inducing apoptosis and are only effective for cycling 
cells. As malignant cells are characterized by an impressive ability to adapt to the environment, 
apoptosis-resistant clones frequently develop during treatment. Each cancer cell has a statistical 
possibility for gaining resistance and therefore the number of malignant cells directly determines 
the overall likelihood of relapse. Furthermore, during subsequent treatment regimens, resistance 
usually occurs more rapidly, and there is a tendency for cross resistance between agents. Therefore, 
new approaches are needed. Importantly, new agents should have novel mechanisms of action, 
thereby lacking cross resistance with currently available treatments. Tumor-targeted oncolytic 
viruses might prove useful in this regard. These viruses have a cytolytic nature, i.e. the replicative 
life cycle of the virus results in host cell destruction.  
The first clinical cancer trial with replicating adenoviruses was done in 1956 with various wild-type 
strains (Smith et al. 1956). More recently, the increased understanding of adenovirus replication and 
its interactions with cellular proteins have inspired the construction of CRAds. Infection of tumor 
cells results in replication, oncolysis, and subsequent release of the virus progeny. Normal tissue is 
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spared due to lack of replication (Figure 6). Importantly, this replication cycle allows dramatic local 
amplification of the input dose, and in theory, a CRAd would replicate until all cancer cells are 
lysed. Conceivably, CRAd released from the tumor tissue might disseminate and infect distant 
metastases. Furthermore, the immunogenicity of adenovirus mediated tumor cell killing could be 
useful for eradication of distant metastases (Todo et al. 1999), and long term anti-tumor immune 
surveillance, but needs to be studied further.  
 
 
Figure 6. Conditionally replicating adenoviruses. a) Infection of tumor cells results in replication, cell lysis, and subsequent 
release of virus progeny. Importantly, replication allows local amplification of the input dose. b) Benign cells are spared due 
to lack of replication. 
 
5.1. Deletion mutant CRAds 
Type I CRAds feature loss-of-function mutations in the virus genome, which are compensated by 
cellular factors present in cancer but not normal cells. For example, this can be achieved by 
incorporating deletions in the immediately-early (E1A) or early (E1B) adenoviral genes resulting in 
mutant E1 proteins unable to bind the cellular proteins necessary for viral replication in normal 
cells, but not in cancer cells. 
The first published CRAd was ONYX-015 (a virus was initially reported as dl1520), which has two 
mutations in the gene coding for the E1B-55 kD protein (Bischoff et al. 1996). The purpose of this 
protein is binding and inactivation of p53 in infected cells, for induction of S-phase, which is 
required for effective virus replication. Thus, this virus should only replicate in cells with an 
aberrant p53-p14ARF pathway, a common feature in human tumors (Ries et al. 2000). While this is 
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still subject to debate, initial studies suggested that this agent replicates more effectively in tumor 
than in normal cells. However, other adenoviral proteins also have direct effects on p53 inhibition 
(e.g. E4orf, E1B-19kD, E1A). Further, E1B-55kD has other viral functions unrelated to p53 binding 
such as viral mRNA transport, which might result in inefficient replication of ONYX-015 in 
comparison to wild-type adenovirus (Dix et al. 2001).  
Ad5-∆24 contains a 24-bp deletion in the constant region 2 (CR2) of E1A, and the modified protein 
is unable to bind the cellular Rb protein for induction of S-phase (Fueyo et al. 2000). Therefore, 
viruses with this type of deletion have reduced ability to overcome the G1-S checkpoint and 
replicate efficiently only in cells where this interaction is not necessary, e.g. tumor cells defective in 
the Rb-p16 pathway. It has been suggested that all human cancers may be deficient in this crucial 
pathway (Sherr. 1996). 
In normal cells, virus associated (VA) RNAs I and II inactivate the RNA-dependent protein kinase 
R (PKR), which otherwise would block protein translation in response to infection. However, an 
activated RAS/MAPK pathway can also inactivate PKR. Cascallo et al. studied a deletion mutant 
CRAd, dl331, which has a deletion in the VAI region, and therefore is unable to replicate efficiently 
in normal cells, but retains RAS/MAPK-dependent replication (Cascallo et al. 2003). 
5.2. Promoter-inducible CRAds 
In type II CRAds, TSPs replace endogenous viral promoters. This restricts viral replication to target 
tissues actively expressing the transcription factors that stimulate the TSP. Usually, a TSP is placed 
to control E1A, but alternatively or in addition, other early genes can also be regulated. Various 
promoters have been used to control viral replication. AvE1a04i, containing the E1A gene under the 
control of α-fetoprotein (AFP) promoter, selectively replicates in hepatocellular carcinomas that 
express AFP (Hallenbeck et al. 1999). The same approach was used for breast cancer with the 
DF3/MUC1 gene promoter (Kurihara et al. 2000), a truncated L-plastin promoter (Zhang et al. 
2002) and estrogen-responsive elements from pS2 gene promoter (Hernandez-Alcoceba et al. 
2000).  
The IAI.3B gene encoding the B-pox protein is highly expressed in ovarian cancer cells. Hamada et 
al. utilized the IAI.3B promoter to control E1A expression (Hamada et al. 2003). The truncated L-
plastin promoter was evaluated in ovarian carcinoma (Zhang et al. 2002). Also, the cox-2 promoter 
has been explored in the context of pancreatic carcinoma and ovarian cancer (Yamamoto et al. 
2003; Kanerva et al. 2004). Telomerase activity is present in almost all human tumors. Therefore, 
tumor-specific human telomerase reverse transcriptase (hTERT) regulated CRAds were shown to 
have oncolytic activity in various types of tumors (Wirth et al. 2003).  
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The midkine differentiation factor promoter was used for advanced neuroblastoma and Ewing’s 
sarcoma (Adachi et al. 2001). OV798 has the carcinoembryogenic antigen (CEA) promoter driving 
E1A expression. It displayed oncolysis of CEA expressing colorectal cancer cells in vitro and in 
vivo (Li et al. 2003). Another interesting approach for treating colorectal cancer was described by 
Fuerer et al. They introduced Tcf transcription factor binding sites in multiple early adenovirus 
promoters, which therefore target the cells with activated wnt signaling pathway (Fuerer and Iggo. 
2002).  
Human prostate specific antigen (PSA) promoter and rat probasin promoters have been utilized for 
prostate cancer specific replication. CV706 has the PSA promoter and enhancer controlling E1A 
expression (Rodriguez et al. 1997), while CV787 has the rat probasin promoter controlling E1A and 
the PSA promoter and enhancer driving E1B (Yu et al. 1999). Further, the replication has been 
controlled by the noncollagenous bone matrix protein osteocalcin (OC) promoter. Ad-OC-E1a has 
been used for treatment of both androgen-dependent and androgen-independent prostate cancer 
bone metastasis (Matsubara et al. 2001).  
Ahmed et al. described a novel CRAd, whose tumor selectivity was based on control of gene 
expression at the level of mRNA stability. They ligated the cox-2 3’ untranslated region (UTR) 
downstream of the E1A gene. This results in mRNA stabilization regulated by an activated 
RAS/MAPK pathway (Ahmed et al. 2003). Of note, also regulatable promoters, such as hypoxia- or 
chemically inducible promoters have been evaluated in the context of CRAds (Cuevas et al. 2003; 
Fechner et al. 2003). Furthermore, CRAds can be transcriptionally targeted to dividing endothelial 
cells, which are present in the tumor vasculature. This offers an alternative approach to anti-
angiogenic therapy for cancer (Savontaus et al. 2002). 
Finally, a novel CRAd combining both type I and type II approaches featured a melanoma-specific 
tyrosinase promoter driving a CR2 deletion-mutated E1A (Nettelbeck et al. 2002). Also, this 
deletion has been combined to E2F1 promoter controlled E1A and E4 expression (Johnson et al. 
2002). 
 
6. CRAds in combination with traditional therapeutics 
Oncolytic tumor killing differs from conventional anticancer therapies, providing a possibility for 
additive or synergistic interactions in a multimodal antitumor approach. Further, the toxicity 
profiles may be different, which could result in enhanced efficacy without significantly increased 
adverse effects.  
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There are several studies suggesting enhanced cell killing activity when CRAds and 
chemotherapeutics were combined. ONYX-015 has been combined in vitro and in vivo with 5-
fluorouracil for treatment of squamous cell carcinoma of the head and neck (SCCHN) and colon 
carcinoma (Heise et al. 1997). Also, ONYX-015 was combined with 5-fluorouracil + cisplatin 
(SCCHN, ovarian cancer) (Heise et al. 2000), cisplatin (SCCHN) (Heise et al. 1997) and cisplatin + 
paclitaxel (non small cell lung cancer) (You et al. 2000). These result suggested potentially 
synergistic interactions with chemotherapeutics. Interestingly, Heise et al. suggested that the 
efficacy is highly dependent on the sequencing of the agents, i.e. simultaneous treatment or 
administration of the virus before 5-fluorouracil + cisplatin were superior to chemotherapy 
followed by virus (Heise et al. 2000). Also, the combination of prostate cancer specific CV787 and 
paclitaxel or docetaxel displayed synergistic efficacy both in vitro and in vivo (Yu et al. 2001).  
Combined ONYX-015 and radiotherapy exhibited additive antitumor cell killing effects in glioma 
(Geoerger et al. 2003), colon cancer (Rogulski et al. 2000a) and cervical cancer (Rogulski et al. 
2000b) xenograft models. Importantly, viral replication in vitro after radiation was not significantly 
inhibited. A ∆24-based virus, Ad5-∆24RGD, displayed enhanced oncolysis for glioma in 
combination with radiation in vitro and in vivo (Lamfers et al. 2002). Further, type II CRAd CV706 
exhibited synergistic antitumor efficacy in combination with radiotherapy (Chen et al. 2001). 
The mechanism of additive or synergistic activity in the multimodal therapy is not known. 
However, few hypotheses have been suggested. First, chemotherapy or radiotherapy might augment 
viral replication. There are some data supporting this view (Yu et al. 2001; Chen et al. 2001), while 
other studies reported no significant effect on the amount of virus produced (Geoerger et al. 2003). 
Secondly, the CRAd might enhance the anti-tumor activity of chemotherapeutic agents or 
radiotherapy. E1A gene expression has been shown to increase cellular sensitivity to chemotherapy 
and radiation through both p53 dependent and independent mechanism (Sanchez-Prieto et al. 1996; 
Duque et al. 1998). Interestingly, certain chemotherapeutic agents have shown to increase CAR 
expression in vitro and in vivo on cancer cells (Hemminki et al. 2003a). Finally, each agent may be 
working independently on different cell populations within the tumor tissue.   
 
7. Armed and infectivity enhanced CRAds 
To further increase the oncolytic effect, transgenes for cytokines (Bauzon et al. 2003) or prodrug-
activating enzymes have been included in CRAds. Such “armed CRAds” couple the lytic capability 
of the virus with the capacity to deliver therapeutic factors into tumor cells. In the prodrug-based 
strategy, genes encoding prodrug activating enzyme are utilized. Common approaches include 
HSV-TK and Escherichia coli cytosine deaminase (CD), which convert systemically administrable 
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and relatively nontoxic prodrugs [ganciclovir (GCV) and 5-fluorocytosine, respectively] into toxic 
products. The activated drugs can spread into surrounding cells (local bystander effect). The HSV-
TK strategy may also allow non-invasive imaging (Hemminki et al. 2002b) and abrogation of virus 
replication in case of toxicity. This approach has led to an enhanced antitumor effect compared to 
virus alone (Rogulski et al. 2000b; Freytag et al. 1998; Wildner et al. 1999; Akbulut et al. 2003; 
Fuerer and Iggo. 2004). However, other studies have suggested that addition of GCV did not 
increase oncolysis, possibly due to the inhibition of viral replication by GCV (Lambright et al. 
2001). Freytag et al. introduced a TK/CD fusion gene in the deleted E1B-55 kD region of ONYX-
015. Further, they combined this double suicide gene therapy to radiotherapy with encouraging 
results (Freytag et al. 1998). 
Most published CRAds rely on CAR for entry into cells. Recently, it has been demonstrated that the 
oncolytic potency of replicating agents is directly determined by their capability for infecting target 
cells (Hemminki et al. 2001a; Douglas et al. 2001). Thus, variable CAR expression on cancer cells 
could hinder CRAd mediated oncolysis. Therefore, methods to circumvent CAR-deficiency and 
improve cell killing have been evaluated in the context of CRAds.  
Ad5-∆24RGD features the 24-bp E1A CR2 deletion, and an RGD-4C modification of the fiber 
(Suzuki et al. 2001). The combination resulted in similar or enhanced oncolytic potency in 
comparison to wild-type virus in various cancer cells in vitro and in vivo (Cripe et al. 2001; Fueyo 
et al. 2003; Witlox et al. 2004). Further, this virus was able to replicate in ovarian cancer primary 
cell spheroids and resulted in significantly prolonged survival in an aggressive orthotopic ovarian 
cancer model (Bauerschmitz et al. 2002b; Lam et al. 2003a). Also, an E1B-55 kD-deleted CRAd 
has been modified with the heparan sulfate-binding polylysine residue at the C-terminus of the fiber 
(Shinoura et al. 1999). The first TSP-controlled, infectivity enhanced CRAd has recently been 
constructed and tested on ovarian and pancreatic cancer substrates (Yamamoto et al. 2003; Kanerva 
et al. 2004). Replicative specificity was achieved with the cox-2 promoter controlling expression of 
E1A, while the fiber was modified with RGD-4C.  
Targeting with adapter molecules has been tested in the context of CRAds. Co-infection of a 
replication-deficient virus coding sCAR-EGF and Ad5-∆24 resulted in enhanced oncolysis 
(Hemminki et al. 2001a). However, this approach did not increase infectivity as a single-component 
oncolytic virus, D24sCAR-EGF, which incorporates the sCAR-EGF fusion protein in the deleted 
E3 region (Hemminki et al. 2003b). This suggests that the expression of biologically active adapter 
proteins can interfere with virus production and oncolysis. In contrast, van Beusechem et al. 
introduced a bispecific single chain (sFv) antibody 425-S11 (recognizes EGFR and the fiber knob) 
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into the E3 region of Ad5-∆24. This secretory retargeting moiety increased the killing of CAR-
deficient glioma cells in vitro and in vivo (van Beusechem et al. 2003).  
 
8. Clinical trials with oncolytic viruses  
8.1. Other oncolytic viruses 
Both naturally occurring and genetically engineered oncolytic viruses have been described. 
Specifically, it has been suggested that some viruses, such as reovirus and Newcastle disease virus, 
might have intrinsic selectivity for replication in tumors. In contrast, to achieve tumor selective 
replication and subsequent oncolysis, HSV-1, vaccinia and adenovirus (CRAd) can be genetically 
attenuated to preferentially replicate in malignant cells.  
Reovirus and Newcastle disease viruses are RNA viruses. During their replication cycle, double-
stranded RNA, a stimulator of PKR, is formed. PKR inhibits protein synthesis and promotes 
apoptosis, thereby controlling the spread of the virus infection.  Double-stranded RNA can also 
stimulate release of interferons (IFNs), which activate PKR in adjacent, uninfected cells. 
Importantly, tumors are frequently defective in the PKR signaling pathway, allowing the replication 
of these viruses in malignant cells. Reoviruses are commonly isolated from the human respiratory 
and gastrointestinal tracts, although they seem to be nonpathogenic. Recently, it has been shown 
that reoviruses replicate in cancer cells with the activated RAS signaling pathway. Therefore, up to 
80% of tumors might be susceptible to reovirus replication. Newcastle disease virus causes 
respiratory and central nervous system infections to fowl. However, to humans it is a mild pathogen 
causing conjunctivitis. Tissue culture-adapted strains of the virus (PV701) show potent oncolytic 
activity in human cancer cells, possibly due to a defect in the IFN signaling pathway. 
HSV-1 and vaccinia virus are double-stranded DNA viruses. HSV-1 is a natural human pathogen 
that can cause recurrent oropharyngeal or genital sores. Pathogenicity is reduced by mutating one or 
more of the crucial virulence genes (e.g. ICP6, γ34.5, UL24, UL56) resulting in replication 
competence only in cycling cells. Due to their neurotropism, oncolytic HSV-1 viruses were initially 
constructed for brain tumor therapy. Nevertheless, preclinical studies have shown efficacy against 
various solid tumors in vitro and in vivo. Vaccinia virus is a member of the poxvirus family. It is 
related to smallpox, and therefore it has been used as a smallpox vaccine. However, vaccinia is a 
mild pathogen, and it may cause rash, fever and body aches. Most genetically modified vaccinia 
viruses have the TK gene deleted, which might help to give selectivity for dividing cells. This 
deletion makes the virus dependent on host cell nucleotides, which are more available in dividing 
cells. Also other viral genes have been mutated to achieve tumor selectivity. 
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8.2. Clinical trials with oncolytic viruses 
The most advanced clinical results are reported for CRAds, and ONYX-015 is the most 
comprehensively clinically evaluated CRAd (Table I). Safety data has been excellent, but 
demonstration of efficacy has been limited. ONYX-015 has been well tolerated at doses up to 2 x 
1013 vp by i.p., intravenous (i.v.), intratumoral and intra-arterial routes. In a phase II study of 
intratumorally administered ONYX-015 in 40 patients with head and neck cancer, 3 complete and 2 
partial responses were reported (Nemunaitis et al. 2001a). In contrast, when the same virus was 
given in combination with 5-fluorouracil and cisplatin, 27% and 36% of patients had complete and 
partial responses (Khuri et al. 2000). There were 11 patients with several tumors, but only the 
largest one was injected with the virus. Thus, the trial included internal control tumors. Only 17% 
of injected tumors had progressed 6 months after treatment initiation, while all the control tumors 
treated with chemotherapy alone had progressed. The phase III trial of this combination for patients 
with recurrent head and neck cancer has been started.  
These results suggested that initial successful clinical applications may feature combination 
treatments. However, most completed trials have employed CRAds such as ONYX-015, with low 
replicativity and therefore low oncolytic potency. Of note, Onyx Pharmaceuticals discontinued their 
therapeutic virus program in order to concentrate in the development of the small molecules 
(http://www.onyx-pharm.com/onyxtech). However, other biotechnology companies have continued 
cGMP quality production and research of ONYX-015 and other CRAds. Further, single agent 
efficacy may be more impressive with more potent viruses. This was well demonstrated by the high 
rate of PSA responses in a preliminary report of a trial featuring systemic treatment of disseminated 
prostate cancer with CG7870 (formerly CV787) (DeWeese et al. 2003).  
All completed trials have evaluated CAR-binding CRAds. As CAR-deficiency may be a frequent 
phenomenon associated with carcinogenesis, this may have decreased the efficacy of approaches 
utilized thus far. The first trial featuring a transductionally targeted CRAd, Ad5-∆24RGD (Suzuki 
et al. 2001), has received National Cancer Institute funding and may soon start enrolling glioma and 
ovarian cancer patients (A Hemminki, personal communication). Further, patient selection has a 
major impact on the displayed efficacy in phase I/II trials. The enrolled patients have been heavily 
pretreated and very often end stage patients, which may weaken the potential for detecting 
responses.  In contrast, the patients with minimal residual disease with the goal being prevetion of 
tumor recurrence might display significant efficacy. 
Several cancer trials have been performed recently with viruses other than adenovirus (Nemunaitis. 
2003a; Hermiston and Kuhn. 2002; Hawkins et al. 2002). Phase I dose-escalation trials of 
intratumoral injection of reovirus (Reolysin) in patients with recurrent malignant glioma and 
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SCCHN are in progress (Kirn et al. 2001; Shah et al. 2003). Passage attenuated Newcastle disease 
virus strain PV701 has been evaluated in a phase I trial of i.v. administration of involving 79 
patients with advanced solid cancers that were unresponsive to standard therapy (Pecora et al. 
2002). The most common side effects were we fever, chills, nausea and vomiting. There were one 
complete and one partial response, and 14 patients had stable disease 4 months. Vaccinia virus has 
been utilized for inducing antitumoral immune responses in addition to tumor selective replication. 
However, no objective systemic antitumoral responses were seen in patients with advanced disease 
(Hawkins et al. 2002; Shah et al. 2003). Furthermore, HSV-1 has been widely evaluated in patients 
with glioma. In two phase I studies no significant toxic effects were reported, but unfortunately, 
there were no responses detected. However, phase II studies are ongoing (Shah et al. 2003; 
Varghese and Rabkin. 2002).           
All of these early phase trials with other oncolytic viruses reported good safety data, while efficacy 
seemed modest at best. Thus, CRAds are currently the most promising oncolytic agents. 
Nevertheless, armed variants of the other oncolytic viruses could improve their efficacy.  
 
 
Table 1. Clinical trials with CRAdsa 
 
 
 
Virus Genetic 
alterations/ 
Concurrent 
treatment 
Phb Pts Routec Tumor 
targetsd 
Resultse Refs 
dl1520 
(same virus 
as ONYX-
015) 
E1B-55 kD 
deletion 
I 22 i.t. SCCHN 1x1011 pfu, 
2 PR 
(Ganly        
et al. 2000) 
ONYX-015 E1B-55 kD 
deletion 
I 23 i.t. Pancreatic 
ca. 
1x1011 pfu, 
no responses 
(Mulvihill   
et al. 2001) 
ONYX-015 E1B-55 kD 
deletion 
I 10 i.v. Metastatic 
solid tumor 
2x1013 vp, 
no responses 
(Nemunaitis 
et al. 2001b) 
ONYX-015 E1B-55 kD 
deletion 
I 16 i.p. Ovarian ca. 1x1011 pfu/d   
x 5d,  
no responses 
(Vasey        
et al. 2002) 
ONYX-015 E1B-55 kD 
deletion       
+/-                    
5-fluorouracil 
and leucovorin 
I 11 i.ha. Colorectal 
ca. metastatic 
to liver 
2x1012 vp, 
1 PR with 
combination 
therapy 
(Reid           
et al. 2001) 
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ONYX-015 E1B-55 kD 
deletion 
I 22 m.w. Premalignant 
oral 
dysplasia 
1x1011 pfu/d   
x 5d, 
followed by 
1x/wk,  
2 CR, 1 PR 
(Rudin        
et al. 2003) 
ONYX-015 E1B-55 kD 
deletion          
+         
irinotecan and      
5-fluorouracil  
I 5 i.v. Colon ca. 2x1012 vp, 
no responses 
(Nemunaitis 
et al. 2003b) 
ONYX-015 E1B-55 kD 
deletion  
+         
interleukin 2 
I 5 i.v. Solid tumor 2x1011 vp, 
no responses 
(Nemunaitis 
et al. 2003b) 
CV706 PSA promoter-
enhancer 
controlling E1A  
I 20 i.t. Prostate ca. 1x1013 vp, 
 ≥50% PSA 
decrease        
in 5/20 pts 
(DeWeese   
et al. 2001) 
Ad5-
CD/TKrep 
E1B-55 kD 
deletion, 
insertion of 
TK/CD  
+                
GCV/                   
5-fluorocytosine 
I 16 i.t. Recurrent 
prostate ca. 
1x1012 vp, 
≥50% PSA 
decrease           
in 3/16 pts 
(Freytag      
et al. 2002) 
Ad5-
CD/TKrep 
E1B-55 kD 
deletion, 
insertion of 
TK/CD  
+                
GCV/                  
5-fluorocytosine  
and radiation 
I 15 i.t. Newly 
diagnosed 
prostate ca. 
1x1012 vp, 
significant 
decline in 
PSA level in     
all pts 
(Freytag      
et al. 2003) 
ONYX-015 E1B-55 kD 
deletion  
+                      
5-fluorouracil        
(in phase II)  
I-II 16 i.t., 
i.ha., 
i.v. 
HCC and  
colorectal ca. 
metastatic to 
liver 
3x1011 pfu, 
no responses,   
in phase II 
50% CEA 
decrease        
in 3/7 pts 
(Habib        
et al. 2001) 
ONYX-015 E1B-55 kD 
deletion 
+                      
5-fluorouracil     
and leucovorin 
II 27 i.ha. Gastro-
intestinal ca. 
metastatic to 
liver 
2x1012 vp, 
3 PR  
(Reid           
et al. 2002) 
ONYX-015 E1B-55 kD 
deletion 
II 40 i.t. SCCHN 2x1011 vp  
for 10 d, 
2 PR, 3 CR 
(Nemunaitis 
et al. 2001a) 
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a Includes clinical cancer gene therapy trials that have completed patient enrollment; b Ph = phase; c i.t. = 
intratumoral, i.v. = intravenous, i.p. = intraperitoneal, i.ha. = intrahepatic artery, m.w. = mouthwash; d SCCHN 
= squamous cell carcinoma of the head and neck, HCC = hepatocellular carcinoma; e vp = viral particle, pfu = 
plaque forming unit, PR = partial response, CR = complete response 
 
 
9. Adenoviral gene therapy trials for ovarian cancer  
9.1. Ovarian cancer 
Ovarian cancer is the fourth most common cancer among women in Finland with 599 new cases 
(including 199 borderline tumors) in 2001. The age-standardized incidence rate was 13.4 per 100 
000 person-years. The median age at diagnosis is 62 years (The Finnish Cancer Registry; 
http://www.cancerregistry.fi). Most cancers of ovary are of epithelial origin, i.e. carcinomas. The 
most common histological type is serous (over 50%), followed by mucinous and endometrioid 
types (15% each). The prognosis of ovarian cancer is poor as approximately 75% of patients are at 
International Federation of Gynecology and Obstetrics (FIGO) stages II-IV at the time of diagnosis. 
The overall 5-year survival rate is 47%, which makes ovarian cancer a leading cause of 
gynecological cancer mortality. However, in women with low-risk stage I epithelial ovarian cancer, 
5-year survival rates can be over 90%. Unfortunately, these rates fall progressively as the disease 
becomes more advanced (to <10% in patients with stage IV malignancy) (Knopf and Kohn. 2001). 
ONYX-015 E1B-55 kD 
deletion  
+             
cisplatin and       
5-fluorouracil  
II 37 i.t. SSCHN 1x1010 pfu/d   
x 5d, 
11 PR, 8 CR 
(Khuri         
et al. 2000) 
ONYX-015 E1B-55 kD 
deletion  
+/-    
gemcitabine 
I-II 21 i.t. Pancreatic 
ca. 
2x1011 vp, 
1x/wk,         
8 cycles 
2 PR 
(Hecht         
et al. 2003) 
ONYX-015 E1B-55 kD 
deletion 
II 18 i.v. Metastatic 
colorectal ca. 
2x1012 vp 
every           
2 weeks, 
no responses 
(Hamid        
et al. 2003) 
CG7870 Rat probasin 
promoter 
controlling E1A, 
PSA promoter 
and enhancer 
driving E1B 
I-II 20 i.t. Locally 
recurrent 
prostate ca. 
1x1013 vp, 
25-50% PSA 
decrease     
in 8/12 
evaluable pts 
(DeWeese    
et al. 2003) 
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In addition to FIGO stage, important prognostic factors include histological type and grade, residual 
disease and patient’s performance status and age (Friedlander. 1998).  
The initial approach to the treatment of ovarian cancer is almost always surgery. The purpose of 
surgery is to establish the diagnosis, to surgically stage the disease, and - in the event of advanced 
disease - to remove as much cancer tissue as possible, i.e. cytoreduce the tumor. Chemotherapeutics 
has been regarded as a standard therapy for majority of patients (Marsden et al. 2000; McGuire and 
Markman. 2003). Lately, the combination of either cisplatin or carboplatin with paclitaxel has been 
a first-line therapy. Also, alternative taxanes, such as docetaxel, have been studied (McGuire and 
Markman. 2003). Further, alternative delivery route via i.p. catheter has been investigated for 
patients with minimal residual disease. However, this approach has not found widespread 
acceptance (Marsden et al. 2000). 
9.2. Adenoviral gene therapy trials for ovarian cancer 
Clearly, novel treatment strategies are needed for this disease. Adenoviral gene therapy is an 
attractive modality for treatment of ovarian cancer because ovarian cancer tends to remain localized 
in the peritoneal cavity, allowing for regional delivery of the vector or virus. In the setting of 
ovarian cancer, Ad21 was among the first clinically evaluated adenoviral gene therapy approaches. 
Ad21 is an E1/E3-deleted adenovirus, which encodes an endoplasmic reticulum localizing anti-
erbB2 single chain intrabody. It was hypothesized that the expressed intrabody traps a cancer 
associated receptor erbB2 to endoplasmic reticulum, and therefore, down-regulates the cell surface 
expression of otherwise overexpressed protein. This approach resulted in induction of apoptosis and 
ovarian cancer cytotoxicity in vitro, and enhanced anti-tumor activity and survival in ovarian cancer 
animal models (Deshane et al. 1994; Deshane et al. 1995a; Deshane et al. 1995b; Deshane et al. 
1996; Deshane et al. 1997). Alvarez et al. analyzed the feasibility of the strategy in phase I ovarian 
cancer trial (Alvarez et al. 2000a). The treatment was well tolerated up to 1011 pfu without dose-
limiting toxicity. Importantly, PCR and RT-PCR analyses from ascites samples demonstrated the 
presence of vector and expression of transgene, however, there was no data identifying the infected 
cells. Further, there were no responses detected. The major disadvantage of this kind of approach is 
a requirement of infecting all cancer cells.  
The prodrug-based strategy utilizes genes encoding prodrug activating enzymes, which convert 
systemically administrable and relatively nontoxic prodrugs into toxic compounds. The HSV-TK-
based suicide gene strategy has a clear advantage as compared to anti-erbB2 single chain intrabody 
approach. The activated drugs can spread into surrounding cells via gap junctions, i.e. the so-called 
local bystander effect. In phase I clinical ovarian cancer trial 14 patients were treated i.p. with 
AdHSV-TK in single dosages from 1x109 to 1x1011 pfu, which was followed by 14 days of i.v. 
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GCV (Alvarez et al. 2000b). Transient vector-associated fever was experienced by 4/14 (29%) 
patients, however, there were no dose-limiting virus-related side effects. Again, the HSV-TK gene 
transfer and transgene expression were detected in peritoneal aspirates. However, there was no 
objective response to treatment, though 5/14 (38%) had a stable disease. Even with the bystander 
effect, the anti-tumor effect could be limited to surface layers of residual tumor. Another phase I 
study combined i.p. delivered HSV-TK-encoding adenovirus to i.v. administered acyclovir and 
concomitant topotecan (Hasenburg et al. 2000). They reported grade 3-4 trombocytopenia and 
neutropenia, which were most likely related to chemotherapy. Again, vector-associated temperature 
elevations were noted. Further, 5/10 patients underwent second-look exploration 20 to 40 days after 
adenovirus delivery. None of the peritoneal biopsies showed residual adenoviral DNA. The median 
survival time was 18.5 months, which compares favorable to previously reported second- and third-
line chemotherapy trials (Hasenburg et al. 2001).  
Mutation of the p53 tumor suppressor gene is one of the most frequent molecular genetic changes in 
cancer. Nearly 70% of advanced stage ovarian cancers contain p53 mutations (Wen et al. 1999; 
Shahin et al. 2000). Subsequently, E1/E3-deleted Ad p53 (SCH 58500) encoding human, wild-type 
p53 was evaluated in phase I/II ovarian cancer trial (Buller et al. 2002). In phase I patients received 
single i.p. injection of virus, while in phase I/II they were treated with multiple doses of the virus up 
to 7.5x1013 vp on 5 consecutive days. Further, in multiple dose schema patients received 3 cycles of 
treatment, and last two of them were in combination with chemotherapy. Treatment was well 
tolerated. The RT-PCR transgene expression data was generated from ascited fluid cell pellets and 
also tissue biopsies, which again might contain non-malignant cells also. However, the presence of 
viral DNA in tumor cells was demonstrated with in situ PCR on a cancer samples from a single 
patient. Finally, 8 of 16 patients in multidose schema demonstrated >50% decrease in serum CA125 
level.  
The poor penetration of the adenoviral vector into solid tumor mass is one restricting factor for 
achieving clinical benefit (Kirn et al. 2001). Replicating viruses can dramatically improve tumor 
penetration. Thus, many CRAds have been preclinically evaluated also for treatment of ovarian 
cancer (Zhang et al. 2002; Hamada et al. 2003; Kanerva et al. 2004; Heise et al. 2000; 
Bauerschmitz et al. 2002b; Lam et al. 2003a; Akbulut et al. 2003; Tsukuda et al. 2002) However, 
only ONYX-015 has entered a phase I clinical trial (Vasey et al. 2002). Sixteen patients received 
from 1 to 4 cycles of ONYX-015 on 5 consecutive days at doses from 1x109 to 1x1011 pfu. One 
patient developed dose-limiting, grade 3 abdominal pain and diarrhea, nevertheless, the maximum-
tolerated dose was not reached. Using PCR, the presence of ONYX-015 DNA in cell-free fraction 
of peritoneal aspirates was demonstrated. However, in situ hybridization on smeared ascites cell 
pellets demonstrated only once viral DNA, and unfortunately, the positive cells did not appear 
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malignant based on size and nuclear morphology. There was no clinical or radiological response in 
any of the patient. 
Importantly, none of the studies above were randomized. Further, there were no clinical complete 
responses. It might be necessary to target adenovirus to non-CAR receptors to achieve reasonable 
transduction levels in clinical setting. Various strategies to retarget adenovirus binding or transgene 
expression in ovarian cancer cells have been analyzed in vitro and in vivo. Rancourt et al. utilized a 
Fab-FGF2 adapter to target HSV-TK expressing adenovirus to FGF receptor-positive ovarian 
cancer cells, which resulted in enhanced survival of ovarian cancer xenograft-bearing mice 
(Rancourt et al. 1998). Consequently, a clinical trial for i.p. treatment of ovarian cancer patients 
with peritoneally disseminated disease with this virus will soon start enrolling patients (A 
Hemminki, personal communication). Incorporation of an RGD-4C peptide in the HI loop of the 
adenovirus vector enhanced the infectivity of ovarian cancer cells in vitro and in vivo (Dmitriev et 
al. 1998; Vanderkwaak et al. 1999; Hemminki et al. 2001b; Hemminki et al. 2002b). Further, RGD-
4C-modified CRAd, Ad5-∆24RGD, was able to replicate in ovarian cancer primary cell spheroids 
and resulted in significantly prolonged survival in an aggressive orthotopic ovarian cancer model 
(Bauerschmitz et al. 2002b; Lam et al. 2003a). Of note, also Ad5-∆24RGD is entering a multi-
center phase I clinical trial for treatment of ovarian cancer (A Hemminki, personal communication).
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AIMS OF THE STUDY 
 
 
1. To measure cell surface expression of CAR and the Ad3 receptor on ovarian cancer cells, 
and to evaluate if there is a correlation with transgene expression mediated by 
adenoviruses that bind to the respective receptors. (I) 
 
2. To evaluate murine liver toxicity, blood clearance and biodistribution, and to assess gene 
transfer efficiency to human primary ovarian cancer cells and in a murine model of ovarian 
cancer with the Ad3 receptor targeted adenovirus. (II) 
 
3. To construct a CRAd retargeted to the Ad3 receptor, Ad5/3-∆24, and to evaluate its 
oncolytic potency in vitro and in vivo. (III) 
 
4. To construct Ad5/3-∆24-hCEA encoding a marker peptide (soluble hCEA) measurable in 
tissue culture fluid or in plasma, and to evaluate replication kinetics of the virus in vitro 
and in vivo. To combine non-invasive imaging of the tumor with the analysis of the marker 
peptide to achieve dual-modality monitoring of virus efficacy. (IV) 
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MATERIALS AND METHODS 
Detailed description of used methodology can be found in the original publications. 
 
1. Cell lines and primary ovarian cancer cells (I-IV)  
Table 2. The list of human cell lines used in this study 
Cell line Description Source Used in 
293 Transformed embryonic  
kidney cells 
Microbix (Toronto, Canada) I, II, III, IV 
911 Transformed embryonic 
retinoblasts  
Dr. AJ van der Eb (University 
of Leiden, the Netherlands) 
III, IV  
AG07086A Mesothelial cells Coriell Cell Repositories 
(Gamden, NJ) 
II 
AG07090B Mesothelial cells Coriell Cell Repositories  II 
A549 
(CCL-185) 
Lung adenocarcinoma ATCC (Manassas, VA) III, IV 
PA-1  
(CRL-1572) 
Ovarian teratocarcinoma ATCC I 
ES-2  
(CRL-1978) 
Ovarian adenocarcinoma ATCC III 
OV-3   
(HTB-75) 
Ovarian adenocarcinoma ATCC III 
SKOV3.ip1 Ovarian adenocarcinoma Dr. J Price (M.D. Anderson 
Cancer Center, Houston, TX)  
I, II, III, IV 
Hey Ovarian adenocarcinoma Dr. J Wolf (M.D. Anderson 
Cancer Center, Houston, TX)  
I, II, III 
OV-4 Ovarian adenocarcinoma Dr. TJ Eberlein (Harvard 
Medical School, Boston, MA) 
I, II, III 
SKOV3-luc Ovarian adenocarcinoma  cells 
expressing firefly luciferase 
Dr. R Negrin (Stanford 
Medical School, CA) 
III, IV 
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Primary ovarian adenocarcinoma cells were purified by an immunomagnetic-based method from 
malignant ascites fluid samples from patients undergoing a procedure for ovarian cancer at the  
University of Alabama at Birmingham Hospital (Barker et al. 2001). Briefly, ovarian cancer cells 
were bound with a murine anti-TAG-72-antibody (CC-49, a generous gift from Dr. J Schlom, 
National Institute of Health, Bethesda, MD) and then collected with magnetic beads coated with 
anti-mouse-IgG (Pan Mouse IgG Dynabead, Dynal AS, Oslo, Norway) (I, II, III).  
 
2. The adenovirus vectors and replicating adenoviruses (I-IV) 
Table 3. The list of the adenovirus vectors used in this study 
Virus  Description Source Used in 
Ad5luc1 E1/E3-deleted, a luc gene under the CMV 
promoter in place of E1 
(Krasnykh 
et al. 2001) 
I, II 
Ad5/3luc1 E1/E3-deleted, a luc gene under the CMV 
promoter in place of E1,  
chimeric fiber with the tail and shaft from Ad5 
and the knob domain from Ad3 
This study 
(I) 
I, II 
Ad5lucRGD E1/E3-deleted, a luc gene under the CMV 
promoter in place of E1, 
RGD-4C modification in the HI loop of  
the knob domain 
(Dmitriev 
et al. 1998) 
II 
AdCMVHSV-TK E1/E3-deleted, the HSV-TK gene under the 
CMV promoter in place of E1 
(Rosenfeld 
et al. 1995) 
III 
 
Table 4. The list of the CRAds used in this study 
 
Virus  Description Source Used in 
Ad5-∆24E3 24-bp deletion in CR2 of E1A (Suzuki  
et al. 2002) 
III 
Ad5-∆24RGD 24-bp deletion in CR2 of E1A, 
RGD-4C modification in the HI loop of 
the knob domain 
(Suzuki  
et al. 2001) 
III 
Ad5/3-∆24 24-bp deletion in CR2 of E1A, 
chimeric fiber with the tail and shaft from Ad5 
and the knob domain from Ad3 
This study 
(III) 
III 
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Ad5/3-∆24-hCEA 24-bp deletion in CR2 of E1A,                  
chimeric fibers with tail and shaft from Ad5 and 
knob domain from Ad3,  
hCEA cDNA in a partially deleted E3 region 
This study 
(IV) 
IV 
Ad5/3-∆24∆E3 24-bp deletion in CR2 of E1A,                  
chimeric fibers with tail and shaft from Ad5 and 
knob domain from Ad3,   
E3 region deleted 
This study 
(IV) 
IV 
 
 
Table 5. The plasmids used for cloning of the viruses 
Plasmid Description Source Used in 
pNEB.PK.F5/3 A fiber shuttle vector, containing an Ad5 tail and 
shaft and Ad3 knob  
(Krasnykh 
et al. 1996) 
I, III 
pTU.5/3 E1-deleted Ad5 genome with the chimeric fiber (Uil et al. 
2003) 
III 
pShuttle∆24 A shuttle plasmid containing 24-bp deletion  
in CR2 of E1A 
(Suzuki  
et al. 2002) 
III, IV 
pAdEasy-1.5/3 E1/E3-deleted Ad5 genome with the chimeric 
fiber  
This study 
(IV) 
IV 
pAdEasy-1.5/3-
∆24∆E3 
E3-deleted Ad5 genome with 24-bp deletion in 
CR2 of E1A and  the chimeric fiber 
This study 
(IV) 
IV 
pTHSN A shuttle plasmid containing the E3 region  This study 
(IV) 
IV 
pTHSN-hCEA A shuttle plasmid containing a cDNA encoding 
hCEA inserted in the partially deleted E3 region 
This study 
(IV) 
IV 
pAdEasy-1.5/3-
∆24-hCEA 
Ad5 genome with 24-bp deletion in CR2 of E1A, 
cDNA encoding hCEA inserted in the partially 
deleted E3 region, and the chimeric fiber 
This study 
(IV) 
IV 
 
2.1. Construction of Ad5/3-∆24 (III) 
pNEB.PK.F5/3 was digested with PacI and KpnI, followed by cotransformation into Escherichia 
coli for homologous recombination with a SwaI-linearized plasmid containing an E1-deleted Ad5 
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genome. This resulted in pTU.5/3. In order to create Ad5/3-∆24, pShuttle∆24 was linearized with 
PacI/PmeI and cotransfected into 911 cells with PacI-linearized pTU.5/3 to rescue Ad5/3-∆24. 
2.2. Construction of Ad5/3-∆24∆E3 and Ad5/3-∆24-hCEA (IV)  
pShuttle∆24 was linearized with PmeI and homologous recombination in E.coli was performed 
with pAdEasy-1.5/3. The Ad5/3-∆24∆E3 virus genome was released by PacI digestion and 
transfection to 911 cells. In order to insert hCEA gene into E3 region, pTHSN was digested with 
SunI/MunI creating a 965-bp deletion in E3 region. cDNA encoding the extracellular domain of 
hCEA (2031-bp) was amplified by PCR generating SunI/MunI restriction enzymes sites flanking 
the gene (CEA(F): 5’-ACGTCGTACGATGGAGTCTCCCTCGGCCCCT-3’, CEA(R): 5’-
TGTGCAATTGCTATGCAGAGACTGTGATGCTCTTG-3’) and then inserted into SunI/MunI-
digested pTHSN. pAdEasy-1.5/3-∆24-hCEA was generated by homologous recombination in E.coli 
between FspI-linearized pTHSN-hCEA and SrfI-linearized pAdEasy-1.5/3-∆24. Ad5/3-∆24-hCEA 
was rescued as above. 
2.3. High titer production of the viruses  
Propagation of the adenovirus vectors and CRAds was performed on 293 and A549 cells, 
respectively. All viruses were purified on cesium chloride gradients. The vp concentration was 
determined at 260 nm, and standard plaque assay on 293 cells was performed to determine 
infectious particles. 
 
3. In vitro experiments in this study  
3.1. Adenovirus-mediated gene transfer assays (I, II) 
Cells were infected for 30 min at room temperature. Cells were washed once, and growth medium 
was added. After 24 hrs of incubation at 37˚C, luciferase assay was performed (Luciferase Assay 
System, Promega, Madison, WI). The protein concentration was determined using a Bio-Rad DC 
protein assay kit (Bio-Rad, Hercules, CA) to allow normalization of the gene expression data for 
the amount of protein. In knob-blocking experiment, monolayers of SKOV3.ip1 cells were 
preincubated with increasing concentrations of Ad5 or Ad3 knob for 10 min at room temperature. 
To analyze the effect of pre-existing neutralizing antibodies, viruses were preincubated for 10 min 
at room temperature with malignant ascites. Then, cell monolayers were infected for 1 hr at 37˚C, 
followed by incubation and luciferase assay as above.  
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3.2. Determination of receptor expression by flow cytometry (I) 
Cells were incubated with either Ad5 or Ad3 recombinant knob protein with 6-His tag. Thereafter, 
the knob-binding was detected with primary Tetra-His-Antibody (Qiagen, Valencia, CA) and 
secondary fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG (Sigma, St Louis, MO). 
2.6 µg/ml Propidium Iodide (Sigma) was added to sort out dead cells from the sample, then 2x104 
cells (OV-4) or 104 cells (other cell lines) were analyzed immediately by flow cytometry at the 
University of Alabama at Birmingham FACS Core Facility.  
3.3. In vitro cytotoxicity assay (III) 
Cells were infected with CRAds and E1-deleted control virus for 1 h at 37ºC. Thereafter, cells were 
incubated with growth medium with 5% fetal bovine serum until almost complete cell killing was 
visually evident at the lowest dose of any virus. Cell viability was measured using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (MTS assay, Promega).  
3.4. Quantitating virus replication (III)  
Primary ovarian cancer cells were purified and cultured as three dimensional spheroids overnight as 
described (Lam et al. 2003a). Briefly, cells were suspended in growth medium in 3% agar coated 
flasks and incubated on a rocking platform. The next day, spheroids were infected for 1 h at 37ºC. 
Cells and growth medium were harvested and frozen at indicated time-points. To quantitate the 
viral copy number, DNA was purified from spheroid suspension (cellular and growth medium 
fractions together) using a DNeasy Tissue Kit (Qiagen), and the E4 copy number and human β-
actin were determined with quantitative PCR as described (Hemminki et al. 2001b). The 
background values (uninfected spheroids) were subtracted at each time point. To estimate total 
virus production by the spheroids, cumulative virus copy number was calculated.  
 
Table 6. Primers and probes used for quantitative PCR 
Adenoviral E4 Used in 
Forward: 5’-GGAGTGCGCCGAGACAAC-3’ II, III, IV 
Reverse: 5’-ACTACGTCCGGCGTTCCAT-3’ II, III, IV 
Probe: 5’-TGGCATGACACTACGACCAACACGATCT-3’ II, III, IV 
Human β-actin  
Forward: 5’-TAAGTAGGCGCACAGTAGGTCTGA-3’ III, IV 
Reverse: 5’-AAAGTGCAAAGAACACGGCTAAGT-3’ III, IV 
Probe: 5’-CAGACTCCCCATCCCAAGACCCCA-3’ III, IV 
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Mouse β-actin  
Forward: 5’-CGAGCGGTTCCGATGC-3’ II 
Reverse: 5’-TGGATGCCACAGGATTCCAT-3’ II 
Probe: 5’-AGGCTCTTTTCCAGCCTTCCTTCTTGG-3’ II 
 
3.5. In vitro growth kinetics of Ad5/3-∆24-hCEA (IV) 
Cells were infected with Ad5/3-∆24-hCEA for 1 h at 37ºC. At indicated time points supernatant 
was collected, and hCEA level was measured in Mayo Clinic Central Clinical Laboratory using the 
Bayer Centaur Immunoassay System as described (Peng et al. 2002a). Cells were collected and 
virus copy number was quantitated as above.  
 
4. Preclinical, in vivo evaluation of the viruses (II, III, IV)  
Mice were obtained from University of Alabama at Birmingham CFAR SCID Mouse Core Facility 
or Charles River Laboratories (Wilmington, MA) at 3-4 weeks age and quarantined for 2 weeks. 
Mice were kept under pathogen-free conditions according to the American Association for 
Accreditation of Laboratory Animal Care guidelines. Animal protocols were reviewed and 
approved by the Institutional Animal Care and Use Committee of University of Alabama at 
Birmingham. 
 
Table 7. In vivo experiments performed with female mice 
Study Route Dose (vp/ml) Mice Method Used in 
Liver toxicity, 
ALT, AST release 
i.v. 5 x 1010 C57BL/6 GO&GP-Trans-
aminase Kit, Sigma 
II 
Liver toxicity, 
histopathology 
i.v. 5 x 1010 C57BL/6 H&E staining II 
Liver toxicity,  
liver transduction 
i.v. 5 x 1010 C57BL/6 Luciferase analysis II 
Blood clearance i.v. 5 x 1010 C57BL/6 Luciferase analysis 
from cells infected 
with plasma 
II 
Biodistribution i.p. 5 x 1010 CB17 
SCID 
Luciferase analysis 
from organs 
II 
Liver transduction i.p. 5 x 1010 CB17 
SCID 
Quantitative PCR for 
viral DNA 
II 
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Transduction,  
s.c. tumor 
i.t. 2.5 x 109 CD-1 
nude 
Luciferase analysis II 
Therapeutic 
efficacy, i.p. tumor 
i.p. 1x 3 x 107 CB17 
SCID 
Survival III 
Therapeutic 
efficacy, i.p. tumor 
i.p. 3x 1 x 108 CB17 
SCID 
Survival III 
Imaging of 
therapeutic response  
i.p. 3 x 107 CB17 
SCID 
Bioluminescence 
imaging 
III 
Virus replication 
kinetics 
i.p. 4x 1x 108 CB17 
SCID 
Plasma hCEA level, 
ELISA 
IV 
Imaging of 
therapeutic response, 
viral replication 
kinetics 
i.p. 4x 1x 108 CB17 
SCID 
Bioluminescence 
imaging, 
plasma hCEA level, 
ELISA 
IV 
 
ALT = alanine aminotransferase, AST = asparate aminotransferase, i.p. = intraperitoneal, i.t. = intratumoral, 
i.v. = intravenous, s.c. = subcutaneous 
 
5. Statistics (II, III, IV) 
All statistical analyses were performed using statistical analysis software SAS v.8.2 or v.9.0 (SAS 
Institute, Cary, NY). P value of <0.05 was deemed statistically significant. The differences among 
groups were assessed with the Kruskal-Wallis test. When significant differences were detected, 
pair-wise comparisons between groups were performed with the Wilcoxon two-sample test (II). 
The results with Ad5/3-∆24 group in MTS assay were compared to the other groups using two-
tailed T-test (III). Survival data were plotted on a Kaplan-Meier curve, and the comparison between 
groups by the log-rank procedure and χ2 testing (III, IV). For comparison of tumor size with 
bioluminescence data we constructed a repeated measures linear model that tested for the effects of 
time, treatment group and the interaction of treatment group and time on emitted light. For 
comparison of mean tumor bioluminescence within each treatment group on each time-point with 
baseline, we used the Wilcoxon-rank sum test (IV).  
  
                                                                  41   
RESULTS AND DISCUSSION 
 
1. Expression of adenovirus serotype 5 and 3 receptors on ovarian cancer cells (I) 
To evaluate the receptor binding properties of adenovirus vectors containing a firefly luciferase 
transgene cassette in the deleted E1-region with either the native Ad5 fiber protein (Ad5luc1) or a 
chimeric fiber with the knob from Ad3 fiber (Ad5/3luc1), infections of SKOV3.ip1 cells were 
performed in the presence of purified, trimeric recombinant Ad5 and Ad3 knob proteins (Figure 1 
in Study I). The relevant knob protein was able to block transgene expression in a dose-dependent 
manner up to 85%, while the irrelevant knob had only minimal effects. Our results support the 
existence of a distinct receptor for Ad3, as suggested previously (Stevenson et al. 1995; Roelvink et 
al. 1998). More importantly, these results confirm that Ad5/3luc1 is retargeted to the Ad3 receptor. 
Recently, it has been suggested that there is a common receptor for subgroup B adenoviruses, 
which Ad3 also belongs to (Segerman et al. 2003a). Specifically, the CD46 membrane cofactor 
protein is proposed as a cellular receptor for many group B serotypes (Segerman et al. 2003b; 
Gaggar et al. 2003). In contrast, recent publication suggests that Ad3 does not use CD46 as an 
attachment receptor (Gaggar et al. 2003). CD46 is a member of a family of glycoproteins acting as 
regulators of complement activation. Interestingly, other members of the this family also serve as 
viral receptors, i.e. CD21 for Epstein-Barr virus (Fingeroth et al. 1984) and CD55 for several 
echoviruses (Bergelson et al. 1994) and coxsackieviruses (Bergelson et al. 1995). 
As the Ad3 receptor is not yet identified, we developed a novel knob binding assay to quantify the 
cell surface expression of CAR and the Ad3 receptor on human ovarian cancer cell lines (Figure 2 
in Study I). For this analysis cells were incubated with recombinant, 6-His-tagged Ad5 knob or Ad3 
knob, followed by flow cytometric analysis. 293 cells were included as a CAR-positive control 
(Dmitriev et al. 1998). In contrast, OV-4 and SKOV3.ip1 have been shown to display moderate or 
low levels of CAR (Dmitriev et al. 1998; Dmitriev et al. 2000). This knob binding assay suggested 
that 293 cells express larger amount of CAR than the Ad3 receptor (38% of cells were FITC 
positive after incubation with Ad5 knob versus 17% with Ad3 knob). In human ovarian 
adenocarcinoma cell lines OV-4 and SKOV3.ip1, the Ad3 receptor was detected in 95% and 48% 
of cells, whereas 32% and 0.7%, respectively, were positive for CAR. These results suggest higher 
expression of the Ad3 receptor relative to CAR on human ovarian adenocarcinoma lines. 
Subsequently, high expression of the Ad3 receptor on cancer cells has been demonstrated in the 
context of renal cancer and melanoma using same method (Haviv et al. 2002; Volk et al. 2003). 
Importantly, the primary melanoma cells from patients demonstrated lower CAR expression than 
the analyzed melanoma cell lines (Volk et al. 2003). 
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2. Infectivity of ovarian cancer cells with modified adenoviruses (I, II) 
We hypothesized that differential expression of CAR and Ad3 receptor would correlate with 
infectivity of wild-type capsid Ad5 and Ad5/3 possessing chimeric fibers. First, we analyzed 
transduction of ovarian carcinoma cell lines in vitro (Figure 3 in Study I). Non-adenocarcinoma cell 
lines expressing slightly more CAR than Ad3 receptor in the knob binding assay (PA-1 
teratocarcinoma and control cell line 293) demonstrated ca. two-fold more luciferase with the 
chimeric virus in the gene transfer assay. Further, transgene expression in adenocarcinoma cell lines 
(OV-4, SKOV3.ip1 and Hey) was two orders of magnitude higher with Ad5/3luc1. Specifically, the 
most prominent infectivity enhancement was seen with OV-4 cells, as Ad5/3 displayed 280-fold 
higher transgene expression. Importantly, the receptor density, as estimated by the knob binding 
assay, roughly correlated with reporter gene expression. Thus, the binding to the primary receptor 
appears to be important factor determining the efficiency of adenovirus-based gene delivery to 
target cells. Nevertheless, there are other receptors, which might mediate the initial binding of Ad5. 
Recent studies have suggested that MHC I (Hong et al. 1997) and HSG (Dechecchi et al. 2001; 
Smith et al. 2003) may be involved in the virus binding. Furthermore, expression of αvβ or α3β1 
integrins may affect the infectivity of cells by adenovirus (Mathias et al. 1998; Salone et al. 2003). 
Similarly, Ad5/3 fiber knob binds to the Ad3 receptor, but there might be more interactions with 
other cellular receptors. Further, Shayakhmetov et al. concluded that the interaction between the 
knob protein and the primary receptor determines the intracellular trafficking route (Shayakhmetov 
et al. 2003). Thus, the significant enhancement in transgene expression might partly reflect faster or 
more efficient intracellular behavior of the chimeric virus. However, there are earlier studies 
showing the importance of the whole fiber protein (Miyazawa et al. 1999). Further, the fiber shaft 
length has an impact on virus tropism. Seki et al. showed that the artificial extension of the Ad5 
shaft inhibits infectivity of CAR-expressing cells (Seki et al. 2002). The Ad5 shaft might be 
beneficial for internalization (allowing easy interaction of penton base RGD and cellular integrins) 
and intracellular trafficking of the virus. Nevertheless, our promising results with the Ad5/3 
chimeric vectors displaying Ad3 knob/Ad5 shaft suggest that it may be a useful combination for 
avoiding the problems with CAR deficiency while retaining the high gene transfer capacity of Ad5. 
An important recent revelation has been that primary tumor cells express highly variable and often 
low amounts of CAR, although the corresponding cancer cell lines might be transducible with Ad5 
(reviewed in Bauerschmitz et al. 2002a). Thus, it is crucial to analyze clinical samples for reliable 
preclinical estimation of efficacy. For this purpose, we have developed a purification method that 
typically yields >95% pure population of cancer cells (Barker et al. 2001). We analyzed the purified 
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primary cells without passaging which could help avoid confounding due to geno- and phenotypic 
changes involved in the clonal selection process. Altogether nine patient samples used in this study 
demonstrated from 5- to 50-fold higher transgene expression when infected with Ad5/3luc1 in 
comparison to Ad5luc1 (Figure 4 in Study I, Figure 4 and Table 2 in Study II). Importantly, in all 
cases, Ad5/3luc1 was superior to Ad5lucRGD, which has displayed enhanced infectivity in various 
carcinomas (Dmitriev et al. 1998; Vanderkwaak et al. 1999; Kasono et al. 1999; Wesseling et al. 
2001a; Hemminki et al. 2001b; Hemminki et al. 2002b; Grill et al. 2001; Cripe et al. 2001). Thus, 
an augmentation of luciferase activity was observed with the modified vector, but to somewhat 
smaller extent than with ovarian adenocarcinoma cell lines.  
There are increasing recent data obtained suggesting low CAR expression on ovarian cancer cells 
(You et al. 2001; Dmitriev et al. 1998; Kelly et al. 2000; Vanderkwaak et al. 1999; Zeimet et al. 
2002). As with ovarian cancer, variable expression of CAR is documented in many other cancer 
types such as glioma, melanoma, bladder cancer, rhabdomyosarcoma, pancreatic cancer, SCCHN, 
prostate cancer, osteosarcoma and colorectal cancer (Miller et al. 1998; Li et al. 1999; Cripe et al. 
2001; Hemmi et al. 1998; Kelly et al. 2000; Fechner et al. 2000; Rauen et al. 2002; Kasono et al. 
1999; Grill et al. 2001; Wesseling et al. 2001a; Witlox et al. 2002). Interestingly, previous studies 
suggest that CAR may act as a tumor suppressor, which could be linked to the frequent down-
regulation seen in highly tumorigenic cells (Okegawa et al. 2000). Our results suggest that 
expression of CAR versus the Ad3 receptor is different on human ovarian cancer cells, and the 
density of Ad3 receptor is often higher. Although the receptor and its function are unknown, this 
might suggest that the Ad3 receptor is unrelated to carcinogenesis. Malignant progression might not 
affect its expression level, and thus, Ad3 receptor mediated gene transfer could be advantageous in 
the context of advanced cancer. 
In an animal model of ovarian cancer, Ad5luc1, Ad5/3luc1 or Ad5lucRGD were injected into 
established s.c. Hey cell tumors (Figure 6 in Study II). Both fiber modified vectors demonstrated 
significantly enhanced transgene expression in comparison to Ad5luc1 (versus Ad5/3luc1, P = 
0.0064; versus Ad5lucRGD, P = 0.0014). Of note, the difference between Ad5/3 and Ad5 in vivo 
was 4-fold compared to over 100-fold increase in vitro. However, xenografts contain variable 
amounts of host stromal cells, whose receptor expression levels affect the infectivity of the 
xenograft as a whole. 
These results indicate that modification of the Ad5 fiber with an RGD-4C motif in the HI-loop or 
swapping the knob for a serotype 3 knob can lead to significant enhancements in transduction of 
purified primary ovarian cancer cells and in vivo. Also, as the 5/3 chimera was superior to the 
RGD-4C, it is the best available genetic retargeting moiety for ovarian cancer. Subsequently, the 
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same phenomenon has been noted in the context of renal cancer and melanoma (Haviv et al. 2002; 
Volk et al. 2003). 
At diagnosis, most ovarian cancer patients have ascites fluid. Previous studies have suggested 
partial escape of RGD-4C modified viruses from pre-existing neutralizing anti-adenovirus 
antibodies present in malignant ascites (Blackwell et al. 2000; Hemminki et al. 2001b). Here, we 
showed that also Ad5/3luc1 is able to circumvent neutralization (Figure 5 and Table 3 in Study II). 
In fact, in the presence of ascites, gene transfer was improved up to 3 orders of magnitude in 
comparison to Ad5luc1. The level of neutralizing anti-Ad3 antibodies in ascites is unknown, but in 
the general population, the prevalence of total serum anti-Ad3 antibodies seems to be comparable to 
that of anti-Ad5 (Vogels et al. 2003). However, in parallel to what has been suggested for RGD-4C 
modified adenoviruses, the chimeric nature of the Ad5/3luc1 fiber may allow escape from many of 
the anti-Ad3-fiber neutralizing antibodies, as such antibodies are often conformation sensitive. 
Further, it has been suggested that effective neutralization requires concerted action of anti-fiber, 
anti-penton and anti-hexon antibodies (Hemminki et al. 2002c). This could help explain the 
impressive escape from neutralization seen in our experiments.  
 
3. Liver toxicity and blood clearance rates of fiber modified adenoviruses (II) 
In mice, the liver is the major organ responsible for adenovirus clearance, and could therefore be an 
important organ in regard to potential clinical toxicity in humans (Lieber et al. 1997; Zhang et al. 
2001; Tao et al. 2001). Kupffer cells have an important role in clearing adenovirus from the blood 
but their uptake capacity can be saturated which leads to a non-linear dose effect at approximately 
2x1010 vp in mice (Tao et al. 2001). Only after saturation is achieved, are hepatocytes and other 
tissues transduced effectively. To evaluate immediate and early liver toxicity, we injected 5x1010 vp 
of Ad5luc1, Ad5/3luc1 or Ad5lucRGD, and analyzed serum transaminases, liver histopathology 
and transgene expression at 72 hours (Figure 1 and Table 1 in Study II). In general, only minor 
differences were seen, suggesting that the toxicity of tropism modified viruses does not 
significantly differ from Ad5. Ad5 has been administered i.v., i.p., intra-arterially and 
intratumorally in large doses in clinical trials without significant toxicity (Hemminki and Alvarez. 
2002a). Thus, toxicity similar to Ad5 could predict a good safety profile for these tropism modified 
viruses.  
All viruses caused moderate release of transaminases, with values 3-fold higher than without virus. 
There were no significant differences between the groups. Histopathological analysis revealed 
fewer cytomorphologic hepatic findings with Ad5/3luc1. In the Ad5luc1 group, mild abnormalities 
were found, a few portal triads displayed mild chronic inflammation, some vascular leakage, and 
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mild scattered hepatocyte drop-out and necrosis within the parenchyma. Ad5/3luc1 caused only 
minimal changes, rare portal triad chronic inflammation, mild scattered parenchymal inflammation, 
and focal hepatocyte necrosis. Mice injected with Ad5lucRGD had focal hepatocyte necrosis, 
congestion, and moderate portal triad chronic inflammation, but no parenchymal inflammation. 
Transgene expression in the livers was slightly lower after injection with Ad5lucRGD and 
Ad5/3luc1 in comparison to Ad5luc1 (P = 0.0472 and not significant, respectively), which probably 
reflects differences in functional titers, as the ratio of vp/infectious particles was 5.2, 46 and 51 for 
Ad5luc1, Ad5/3luc1 and Ad5lucRGD, respectively. 
Viruses and other foreign particles in the blood are cleared mostly by Kupffer cells (Worgall et al. 
1997; Alemany et al. 2000). Further, the blood clearance of adenovirus is effective, with a half-life 
of less than 2 min after a single i.v. injection (Alemany et al. 2000). We compared the blood 
clearance rates of the fiber modified viruses to Ad5luc1 by collecting plasma samples 1-60 min 
after i.v. virus injection, and found no differences (Figure 1G in Study II). Further, the clearance 
rate of Ad5luc1 was similar to what has been reported by other groups (Alemany et al. 2000; 
Sakurai et al. 2003).  
 
4. Biodistribution of fiber modified adenoviral vectors (II) 
To obtain preclinical data on the biodistribution of the fiber modified viruses in the context of i.p. 
administration, we performed i.p. injection into orthotopic ovarian cancer tumor bearing mice 
(Figure 2 in Study II). At 48 hours, liver, spleen, kidneys, heart, lungs, peritoneum, brain and 
ovaries were harvested, and luciferase activity and protein concentration of tissue lysates were 
measured. Also, blood samples were collected, and blood cells separated and analyzed. When 
transgene expression was normalized to the amount of tissue analyzed (mg protein), the highest 
transgene expression was seen in the spleen, ovaries, peritoneum and liver. In the liver, luciferase 
activity was higher with Ad5/3luc1 in comparison to Ad5luc1, but the opposite was true after i.v. 
injection. This might result from the lower peritoneal uptake of Ad5/3luc1, subsequently allowing 
entry of Ad5/3luc1 into the circulation and eventually into the liver. We estimated the total uptake 
of virus by organ. The liver had the highest total transgene expression, followed by spleen, kidneys 
and ovaries. These results are in accordance with previous reports describing liver as the main 
organ expressing transgene in mice after i.v. injection of adenovirus (Wood et al. 1999; Reynolds et 
al. 1999). Further, the pattern for i.p. biodistribution of Ad5 has been subsequently corroborated by 
Barker et al. (Barker et al. 2003b). 
Quantitative PCR was performed to detect virus copies in the liver. In contrast to the transgene 
expression data, fewer copies of Ad5/3luc1 were detected in the liver in comparison to Ad5luc1. 
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These findings could reflect differences in uptake by Kupffer cells versus hepatocyte transduction. 
Kupffer cells are generally reported to be ineffective in transgene expression (Tao et al. 2001; 
Wolff et al. 1997). Thus, if Ad5luc1 has higher relative tropism for Kupffer cells in comparison to 
Ad5/3luc1, the result could be less transgene expression but higher copy number. This is supported 
by the higher liver toxicity seen with Ad5luc1. Kupffer cells are the main cells mediating 
immunological responses in the liver and lower uptake could result in less inflammation (Zhang et 
al. 2001; Wolff et al. 1997). Clearly, this needs to be investigated in more detail in animals and 
more importantly, in humans. Contributing factors to the findings could include capsid dependent 
differences during post-entry steps. It is not well understood how adenovirus induces endosomal 
lysis and transport of its DNA to the nucleus, but it seems likely that the fiber plays a role 
(Shayakhmetov et al. 2003). Conceivably, the rate of degradation of adenovirus by innate immune 
mechanisms could also be a contributing factor. Importantly, the Ad3 receptor targeted virus is not 
circumventing the hepatocyte transduction. Therefore, the mitigation of liver toxicity needs other 
means for detargeting liver (transcriptional targeting). 
All ovarian cancer gene therapy trials published so far have relied on i.p. administration of the 
agent. Thus, the normal tissue that is most closely in immediate contact with the agent is the 
peritoneal lining. We analyzed the infectivity of two human established mesothelial cell lines and 
three fresh primary peritoneum samples in vitro (Figure 3 in Study II). Data obtained in murine i.p. 
biodistribution experiment suggested significantly reduced peritoneal transduction with Ad5/3 
chimera. However, the human mesothelial samples displayed increased infectivity with Ad5/3luc1 
and in some cases, also with Ad5lucRGD. For CAR, it has been shown that the localization of the 
receptor in the context of the three dimensional structure is crucial in determining transduction 
(Walters et al. 1999). The situation could be similar for the Ad3 receptor. In the intact peritoneum, 
the receptor may not be accessible and thus infectivity is low, while in the subconfluent cell 
monolayer, the opposite might be true. Finally, it is likely that human and mouse mesothelial cells 
display different expression patterns of the Ad3 receptor and/or CAR. In any case, it is unclear if 
transduction of the peritoneum is likely to cause severe side effects to patients. In the ovarian 
cancer trials published for far, doses of up to 7.5 x 1013 vp of untargeted virus has been 
administered, and although abdominal pain was reported regularly, it was not dose limiting (Buller 
et al. 2002). 
 
5. In vitro replication and ovarian cancer cell killing efficacy of Ad5/3-∆24 (III) 
The oncolytic potency of replicating agents is directly determined by the capability of infecting 
target cells (Douglas et al. 2001; Hemminki et al. 2001b). Consequently, infectivity enhanced 
CRAds have been constructed. With the aid of additional cellular receptors the oncolytic potency 
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has been increased in preclinical studies. Ad5-∆24RGD (Suzuki et al. 2001) features an RGD-4C 
modification of the HI loop of the knob, which allows binding to αvβ integrins, that are regularly 
expressed and often overexpressed on ovarian cancer cells (Dmitriev et al. 1998; Vanderkwaak et 
al. 1999; Hemminki et al. 2001b) and tumor vasculature (Arap et al. 1998). In the context of 
ovarian cancer, Ad5-∆24RGD demonstrated impressive oncolytic potential, and significantly 
increased survival in an animal model (Bauerschmitz et al. 2002b). Consequently, clinical trials 
utilizing this virus for ovarian cancer and glioma are in development (A. Hemminki, personal 
communication). Nevertheless, Ad5-∆24RGD continues to bind CAR, and is therefore not 
retargeted but infectivity enhanced instead.  
In this study, we used fiber chimerism as a retargeting strategy. The Ad5/3-∆24 fiber features the 
knob from serotype 3, and this chimerism results also in enhanced infectivity, which translated into 
increased oncolysis of target cells. In all ovarian adenocarcinoma lines, the quantitative cell killing 
assay showed oncolysis with Ad5/3-∆24, while Ad5-∆24E3 (the isogenic control with the Ad5 
fiber) caused minimal or no cell killing (Figure 2 in Study III). At the highest viral dose, the 
percentage of viable cells remaining with Ad5/3-∆24 was 0.5%, 5.6%, 15%, 2.7% and 5.5% for 
SKOV3.ip1, OV-4, OV-3, Hey and ES-2, respectively, as compared to uninfected wells. On all cell 
lines, oncolysis was significantly improved with fiber-modified Ad5/3-∆24 in comparison to Ad5-
∆24E3 (all P < 0.0033). AdCMVHSV-TK was included as an E1-deleted control, and it did not 
cause oncolysis.  
Ad5/3-∆24 was also compared to Ad5-∆24RGD on SKOV3.ip1 cells (Figure 6 in Study III). At the 
lower dose, Ad5-∆24RGD did not cause significant cell killing, while the percentage of surviving 
cells with Ad5/3-∆24 was 76%, 12% and 1.7% on days 5, 9 and 13 after infection, respectively. 
The difference was significant at every time point (all P ≤ 0.0048). At the higher viral dose, the cell 
viability with Ad5/3-∆24 was 17%, 0.3% and 0.5% at the same time points, while with Ad5-
∆24RGD the respective percentages were 92%, 35% and 1.2%. Statistically significant differences 
were found on days 5 and 9 (P ≤ 0.0022). Oncolytic efficacy was evaluated also on two human 
primary ovarian cancer patient samples cultures as three dimensional spheroids. With patient 
sample A, there was no statistical significance between Ad5/3-∆24 and Ad5-∆24RGD. On patient 
sample B, Ad5/3-∆24 showed earlier cell killing than Ad5-∆24RGD, and the viabilities were 66% 
versus 84% (P = 0.0020) on day 8. In order to achieve effective oncolysis in patient sample B, 
higher viral dose was used (1 vp/cell versus 10 000 vp/cell). Lam et al. have reported similar results 
when they compared a panel of CRAds in the context of ovarian cancer (Lam et al. 2003b). 
Variation of CRAd DNA replication between different patient samples suggests that target tissue 
features, such as surface receptors and endogenous transcription factors, may affect CRAd 
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infectivity and replicativity. Evaluation of such factors may become important in optimizing cancer 
therapy for individual patients.  
 Further, Ad5/3-∆24 was able to replicate in ovarian cancer primary cell spheroids as measured 
with quantitative PCR (Figure 3 in Study III). Importantly, Ad5/3-∆24 was superior to control 
viruses in all patient samples. Therefore, the Ad3 receptor retargeted CRAd effectively replicates in 
primary cancer cells and the replication kinetics are not adversely affected by the genetic fiber 
modification. This is always a danger related to modification of the virus genome, well 
demonstrated by ONYX-015, which expresses mutated E1B-55 kD protein unable to bind and 
inactivate p53 (Bischoff et al. 1996). E1B-55 kD has other functions than p53 binding, and 
therefore, the replication and oncolytic potency of ONYX-015 in comparison to wild-type 
adenovirus is low (Dix et al. 2001).  
 
6. Therapeutic efficacy of Ad5/3-∆24 in an orthotopic ovarian cancer model (III) 
In order to mimic a clinical situation of ovarian cancer, we inoculated advanced i.p. carcinomatosis 
into female CB17 SCID mice, followed by i.p. administration of viruses (Figure 4 in Study III). 
With a single injection of the virus, the median survival was not reached for Ad5/3-∆24, and 50% 
of mice were alive at the end of the experiment on day 135. For Ad5-∆24E3, AdCMVHSV-TK and 
no virus, the median survival times of mice were 96.5, 32 and 33 days, respectively. In comparison 
to the other groups, the overall survival of mice treated with Ad5/3-∆24 was statistically 
significantly improved (log-rank test P < 0.0001). Further, Ad5/3-∆24 allowed 80% survival on day 
114, when all the control mice were dead.  
A schema of three injections on consecutive days was also tested. Again, the median survival of 
mice treated with Ad5/3-∆24 was not reached, and 50% of mice were alive on day 135. For Ad5-
∆24E3, AdCMVHSV-TK and no virus, the median survivals were 41.5, 33 and 32 days, 
respectively. The overall survival was significantly better in mice treated with Ad5/3-∆24 (log-rank 
test P < 0.0001).  
The results obtained here could compare favorably to other reports (Bauerschmitz et al. 2002b; 
Hemminki et al. 2002b; Peng et al. 2002b), though the direct comparison to the other experiments is 
difficult due to different study designs. Interestingly, the survival with Ad5/3-∆24 using single 
injection versus multiple injections was not significantly different. However, the larger dose of 
Ad5-∆24E3 seemed to result in less anti-tumor efficacy in addition to giving increased toxicity. 
This might be due to liver toxicity, as we have seen the same phenomenon with a wild-type Ad5 
(Kanerva et al. 2004). Converted weight/weight into humans, the smaller dose used here would 
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equal ca. 9 x 1010 vp. This is well below the 2 x 1012 vp daily for 5 consecutive days used in a 
CRAd trial, where the maximal tolerated dose was not reached (Vasey et al. 2002).  
 
7. Ad5/3-∆24-hCEA replication in vitro and in vivo (IV) 
As both safety and efficacy relate to persistence and replication of the CRAd, a secretory marker 
protein whose expression correlates with replication might allow non-invasive, repeatable detection 
of these features. Consequently, we constructed a retargeted CRAd featuring a secreted marker 
protein, Ad5/3-∆24-hCEA. We utilized soluble hCEA lacking the hydrophobic C-terminus, which 
would anchor the glycoprotein to the cell membrane. Trackable proteins have been evaluated in the 
context of oncolytic measles viruses (Peng et al. 2002a; Peng et al. 2002b). The results with hCEA 
expressing viruses have been promising in vitro and in vivo. Thus, we wanted to test the approach 
in the setting of replicating adenoviruses.  
The hCEA is a 180 kD glycoprotein, which is expressed by many cancers, and widely used as a 
tumor marker (Goldenberg et al. 1981). Some patients with mucinous ovarian cancer or with 
recurring or stage III disease have detectable levels of hCEA in serum. However, most epithelial 
ovarian cancers do not express hCEA (Panza et al. 1988; Meier et al. 1997). Several possible 
functions have been suggested for the membrane bound form of hCEA. It plays a role in cell 
adhesion, might inhibit cell differentiation and promotes entering G0 phase (Berinstein. 2002). It is 
not known if secreted hCEA has a biological function, but it is widely used as a routine clinical 
marker, which facilitates possible clinical utilization.  
We introduced the hCEA gene into a partially deleted E3 region of the virus (Figure 7). The E3 
region of adenovirus is an early transcription unit encoding at least seven proteins. Interestingly, the 
E3 region is non-essential for viral replication, but the E3 proteins have an important role in the 
regulation of host immune response. Specifically, they inhibit both innate and specific immune 
responses. Further, it is known that deletion of the E3 region results in increased lymphocyte, 
macrophage and monocyte inflammatory responses (Horwitz. 2001). The gp19K binds and 
sequesters MHC I molecules in the endoplasmic reticulum, and therefore prevents the recognition 
of infected cells by cytotoxic T-lymphocytes (CTLs) (Burgert and Kvist. 1985). This reduces CTL 
mediated cytolysis of infected cells. Interestingly, this is another feature shared between the 
adenovirus life cycle and carcinogenesis, as also tumor cells can evade CTL lysis with various 
methods. Thus, a gp19K deleted virus, such as ours, might allow infection and subsequent 
productive replication preferentially in tumor cells, as infected normal cells would be effectively 
recognized by CTLs. This could provide an additional level of selectivity, in addition to the 24-bp 
deletion in E1A, which restricts virus replication to Rb/p16 pathway deficient cells.  
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Figure 7. Schematic illustration of the CRAds used in 
this study. Viruses have a 24-bp deletion in the CR2 of 
the E1A gene, corresponding to the region responsible 
for Rb protein binding. This results in an agent 
replication competent and oncolytic in cells defective in 
Rb/p16 pathway. Ad5-∆24RGD has an RGD-4C motif 
in the HI loop of the fiber knob. The fiber of Ad5/3-∆24, 
Ad5/3-∆24-hCEA and Ad5/3-∆24∆E3 is modified to 
incorporate the serotype 3 knob, while retaining the Ad5 
shaft and tail. In addition, Ad5/3-∆24-hCEA has an 
hCEA gene inserted under control of endogenous viral 
expression signals in the partially deleted E3A region, 
while Ad5/3-∆24∆E3 has the complete E3 region 
deleted. Ad5-∆24RGD, Ad5-∆24E3 and Ad5/3-∆24 
have an intact E3 region. For comparison, wild-type 
adenovirus serotype 5 is also shown. 
 
Another protein deleted in our construct is 6.7K, which is expressed on cellular surface. It induces, 
as a complex with other E3 proteins, down-regulation of TNF-related apoptosis inducing ligand 
(TRAIL) receptor 2 (Benedict et al. 2001). Lack of this protein could further restrict replication of 
the virus in normal cells. The 6.7K/gp19K-deletion has been demonstrated to allow effective 
expression the remaining E3, especially adenoviral death protein (ADP), and structural proteins 
(Hawkins et al. 2001). ADP is expressed later during the virus cycle, and it contributes to cell lysis 
and release of virus progeny (Tollefson et al. 1996). All the E3B proteins inhibit inflammation after 
adenovirus infection in vivo. Importantly, by creating a partial deletion we may be able to enhance 
the selectivity of replication while retaining functions which are conducive for effective oncolysis, 
such as ADP expression. 
In this study, we saw correlation between Ad5/3-∆24-hCEA replication and hCEA production in 
vitro (Figure 1 in Study IV). Further, the 2 kb transgene did not affect replication significantly as 
compared to an E3 deleted control. Importantly, we were able to follow the virus kinetics in vivo in 
i.p. tumor bearing mice (Figure 2 in Study IV). Furthermore, none of the analyzed mice treated with 
a control virus Ad5/3-∆24∆E3 had measurable hCEA concentrations in plasma. All mice treated 
with Ad5/3-∆24-hCEA survived the duration of the experiment, while all untreated mice died due 
to progressive carcinomatosis. In comparison to the untreated mice, the overall survival of mice 
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treated with Ad5/3-∆24-hCEA was improved (log-rank test P < 0.0001). However, none of the 
Ad5/3-∆24-hCEA treated mice were tumor free on day 59 at the end of the experiment. Residual 
i.p. tumors were harvested and virus copies were measured with quantitative PCR. All of the 
Ad5/3-∆24-hCEA treated mice had residual tumors showing up to 2x106 E4 copies per ng of 
cellular β-actin, which suggested virus replication. Only four out of seven mice had residual i.p. 
tumors in Ad5/3-∆24∆E3 treated group. Again, virus was detected in the tumors at high levels (up 
to 3x107 copies). 
Nevertheless, most of the mice treated with Ad5/3-∆24-hCEA displayed increase in plasma 
concentration of hCEA after each virus injection, suggesting productive replication and 
concomitant anti-tumor efficacy. Further, some of them had high plasma hCEA levels during the 
last week of the experiment suggesting strong replication. Interestingly, the hCEA curves of these 
mice were comparable to the others during the first 5 weeks of the experiments. Therefore, it seems 
possible that a balance between virus replication and tumor cell growth was achieved. 
Alternatively, although episomal persistence of adenoviral DNA has been reported (Ehrhardt et al. 
2003), our results suggest that in some cases, tumor cells can acquire resistance to CRAds. Thus, it 
may be possible that although few tumor cells were remaining, they had gained resistance to 
oncolysis but continued to allow Ad5/3-∆24-hCEA DNA replication and subsequent hCEA 
expression. Acquired resistance to cytolysis in ovarian cancer cells has been reported with ONYX-
015 (Kim et al. 2003). Ten weeks after infection of the initially sensitive cells, intracellular hexon 
protein was found in immunofluorescence and FACS analyses. Plaque assay from cell lysate 
demonstrated that cells resistant to cytolysis contained infectious viruses. Further, these cells were 
resistant to the oncolysis of a wild-type Ad2, as well as ONYX-015. However, these cells were 
transducible with E1-deleted adenovirus expressing a lacZ transgene. Thus, there might be a block 
at the lytic stage in these cells (Kim et al. 2003).  
 
8. Dual modality monitoring of CRAd efficacy in vivo (III, IV) 
Non-invasive imaging technologies provide fundamental safety and efficacy information on 
experimental therapy approaches such as gene therapy (Gambhir et al. 1999; Min and Gambhir. 
2004). They may allow more efficient utilization of orthotopic animal models, which otherwise are 
problematic as tumors are not easily accessible to measurements. Further, another important feature 
of non-invasive imaging is the possibility of performing repeated measurements. Therefore, various 
imaging systems have been evaluated (Gambhir et al. 1999; Min and Gambhir. 2004). For example, 
expression of somatostatin receptor subtype 2, coded by an adenovirus vector, can be imaged with 
radioisotope gamma camera after administration of the somatostatin analogue 99mTc-P2045 
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(Hemminki et al. 2002b). Also, optical charge-coupled device (CCD)-imaging has been used to 
detect bioluminescence emitted from D-luciferin reacting with firefly luciferase, coded by an 
adenovirus vector. Other approaches include magnetic resonance and positron-emission 
tomography imaging of positron-emitting ligands such as imaging of sodium/iodide symporter 
transgene after systemic injection of 124I (Groot-Wassink et al. 2004). Furthermore, cancer cells 
expressing reporter genes such as firefly luciferase and green fluorescence protein are useful means 
of following tumor growth.  
We used an orthotopic ovarian cancer model with SKOV3-luc cells, which emit light after i.p. 
administration of D-luciferin (Figure 5 in Study III). Using in vivo bioluminescence imaging, we 
were able to detect and measure i.p. tumor cell killing by the virus. Oncolytic killing of tumor cells 
corresponded with reduction of signal in comparison to control animals. Ad5/3-∆24 treated mice 
initially responded, but then relapsed with s.c. tumors in the needle-tract, an intrinsic defect of this 
animal model (Bauerschmitz et al. 2002b). Nevertheless, the sensitivity of the assays was sufficient 
to allow detection of i.p. cell killing. A further round of imaging was performed without the 
abdominal wall to distinguish the anti-tumor without the confounding s.c. tumors, and found that 
light emitted from the peritoneal cavity was only 4% of the untreated group, suggesting effective 
killing of tumor cells by the virus.  
When plasma hCEA measurements were combined with non-invasive bioluminescence imaging, it 
was possible to correlate virus replication to anti-tumor efficacy (Figure 3 in Study IV). The level 
of emitted light in the Ad5/3-∆24-hCEA treated group did not increase during the experiment, and 
there were no significant differences in mean photon count at any time point versus baseline on day 
7. However, the untreated mice emitted significantly more light over the time period. On day 35 
photon counts had increased up to 131-fold (P = 0.0082, as compared to day 7). Light emitted from 
the peritoneal cavity of Ad5/3-∆24-hCEA treated mice was only 0.4% of the signal of the untreated 
group on day 35 (P = 0.0097, compared to untreated) suggesting effective killing of tumor cells by 
the virus. An overall increase in amount of emitted light over time in the untreated group compared 
to the Ad5/3-∆24-hCEA group was significant (P = 0.0069).  
Concomitant analysis of hCEA levels suggested strong early replication, when the tumors were 
larger. Then, two weeks later the replication was already slowing down, but the photon count was at 
its highest. Finally, both values decreased to baseline in two out of three mice. This suggests that 
hCEA secretion was primarily an early event and at its maximum during the intratumoral and i.p. 
dissemination of the virus, while the actual dying of the cells was a slower process during which 
bioluminescent imaging was still possible. Of note, the detected hCEA in plasma was expressed 
during virus replication in the tumor tissue, as human adenoviruses do not replicate productively in 
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normal murine cells (Blair et al. 1989). However, recent study suggests that murine cancer tissue 
might support some level of replication (Hallden et al. 2003). Importantly, the mice treated with 
control virus did not display measurable levels of hCEA. 
Oncolytic viruses expressing trackable marker proteins might represent a new generation of anti-
tumor agents, which can be dynamically monitored. These would be highly useful tools for 
evaluating the replication, persistence and efficacy of the viruses. 
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SUMMARY AND CONCLUSIONS  
Previous studies have suggested that CAR-deficiency on cancer cells hinders the efficacy of 
adenovirus mediated gene transfer. In order to circumvent this obstacle, we created a retargeted E1-
deleted virus. Specifically, we explored substituting the receptor binding fiber knob domain of Ad5 
with the serotype 3 knob (Ad5/3luc1). This resulted in CAR-independent transduction of ovarian 
cancer cells, as Ad3 has a distinct, but unidentified receptor. Our studies suggest, that in 
comparison to CAR, the Ad3 receptor is expressed at higher levels on ovarian cancer cells, and that 
5/3 serotype chimeras bind to the Ad3 receptor but not to CAR. Importantly, we show that 
exploiting the different tropism of Ad3 leads to enhanced infectivity of ovarian cancer cell lines and 
human primary cancer cells.  
In order to evaluate preclinical toxicity of the Ad5/3 chimera, we explored murine liver toxicity 
after i.v. injection of the virus, and the results were comparable among the groups. Further, we 
evaluated the murine biodistribution after i.p. administration of the viruses. Transgene expression 
was analyzed in the panel of tissues. Significant differences were found in peritoneum, where 
Ad5/3-mediated transgene expression was lower. As a final experiment for the murine safety 
profile, we analyzed virus blood clearance rates after i.v. injection. All the clearance curves were 
similar showing rapid elimination of the virus from the blood stream. 
CRAds represent a novel approach for treating neoplastic diseases. However, the oncolytic potency 
of replicating agents is directly determined by their capability of infecting target cells. Therefore, 
we created the Ad3 receptor retargeted CRAd, i.e. Ad5/3-∆24. This novel oncolytic virus, in 
addition of having the chimeric fiber, expresses a mutant E1A protein unable to bind the Rb protein. 
This binding normally allows adenovirus to induce S-phase entry, needed for virus replication. 
Therefore, Ad5/3-∆24 replicates only in the cancer cells inactive in the Rb/p16 pathway, which 
may include most human cancers. We compared Ad5/3-∆24 to the non-fiber modified isogenic 
control virus. We demonstrated that retargeting a selectively oncolytic adenovirus to the Ad3 
receptor results in improved infectivity of ovarian cancer cells, and overcomes the CAR-deficiency 
on primary cancer cells. Consequently, therapeutic efficacy was dramatically increased in vitro and 
in vivo. Further, we have demonstrated that Ad5/3-∆24 allows cell killing comparable or superior to 
previously described Ad5-∆24RGD.  
However, the major problem in following CRAd efficacy in humans has been the lack of the 
method to repeatably measure CRAd spreading and elimination. To address this issue, we created a 
modified version of Ad5/3-∆24. Ad5/3-∆24-hCEA has an hCEA gene in the partially deleted E3 
region. We demonstrated that during virus replication, soluble hCEA expressed from a selectively 
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oncolytic adenovirus can be measured in growth medium or plasma. Further, this allowed us to 
follow the persistence and anti-tumor efficacy of the virus in vivo. Finally, we compared the 
replication kinetics to tumor eradication evaluated by in vivo imaging. These developments could 
be useful for monitoring CRAd replication in humans, which might increase the quantity and 
quality of correlative data obtained in early phase cancer gene therapy trials. 
Ad5/3-∆24 could be an effective agent for treatment of ovarian cancer and other tumors with an 
inactive Rb/p16 pathway and high expression of the Ad3 receptor. Of note, this approach might be 
further advanced when combined with TSP driving the E1A expression. Clinical trials will 
ultimately show if preclinical advances such as reported here can be translated into similar progress 
in the treatment of cancer patients. 
Effective tumor transduction continues to be the limiting step for achieving clinical results with 
adenovirus vectors. Therefore, it is likely that replicating agents, CRAds and others, will become 
increasingly popular. Another central realization in the adenovirus field has been that the primary 
receptor, CAR, is often expressed at a very low level on primary tumor tissue. Thus, it is likely that 
targeting strategies will significantly improve efficacy in clinical trials. Though other viral vectors 
might be more useful for treatment of hereditary diseases, adenoviruses are highly promising and 
safe agents for oncology, as suggested in number of phase I trials. Finally, considering the 
synergism and a lack of cross resistance of CRAds with chemotherapy and radiation therapy, the 
combination treatment with existing modalities could be the future of CRAds in oncology.  
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